

Writing In-House Medical Device Software in Compliance with EU, UK, and US Regulations

P.S.Cosgriff and M.J.Memmott



<< *Supplementary material* >>

This document is available as a free download from:

<https://www.routledge.com/Writing-In-House-Medical-Device-Software-in-Compliance-with-EU-UK-and/Cosgriff-Memmott/p/book/9781032293509> or

www.softwaremedicaldevice.org.

Document properties

This PDF is **file-protected**. You are free to print the document, but general editing and copy/paste is disabled.

© P.S.Cosgriff & M.J.Memmott, 2024

If you use any of the material in your published work, please quote the source as follows:

P.S.Cosgriff, M.J.Memmott. Writing in-house medical device software in compliance with EU, UK, and US regulations: *Supplementary material*. Available online:

<https://www.routledge.com/Writing-In-House-Medical-Device-Software-in-Compliance-with-EU-UK-and/Cosgriff-Memmott/p/book/9781032293509>¹.

Version 2.7

Last revised: 22 December 2024

¹ The book itself can be purchased from this website, as well as from other main booksellers.

Contents

1. Introduction	4
2. Risk controls	4
2.1. Risk control measures external to the software	4
3. Medical device software	5
3.1 MDCG guidance on MDSW-hardware combinations	5
3.2 Software classification according to IEC 62304	5
3.3 Coding standards.....	5
3.4 “Intended use” and “Indications for use”	5
3.5 In-house development of medical software	6
3.6 Spreadsheet development and testing	6
3.7 Clinical information systems	7
4. Quality management systems.....	8
4.1 Recommended eQMS tools	8
4.2 Quality manual template	8
4.3 FDA formalises the move from QSR to QMSR.....	8
5. Cybersecurity	8
5.1 Legacy devices.....	8
5.2 Finalised FDA cybersecurity guidance 2023.....	9
5.3 CISA’s strategic plan.....	9
5.4 Software Bill of Materials	10
5.5 EU Cybersecurity Resilience Act.....	12
6. Artificial intelligence/machine learning	12
6.1 EU AI Act.....	12
6.2 Diagnostic Assistance Levels (DALs)	15
6.3 Data quality	15
6.4 FDA’s Predetermined Change Control Programme (PCCP)	16
6.5. Foundation models	16
6.6 Machine Learning Good Practice (MLGP) Guidelines	17
6.7 Regulatory issues with generic LLMs	18
6.8 AI in Medical Physics - Roles and responsibilities of medical physicists	19
6.9 Notified Bodies Guidelines on AI (5 th edition).....	19
6.10 Validation standards for the application of AI within a healthcare setting.....	19
6.11 Standards to support the development of AI-enabled medical devices.....	20
6.12 Product liability considerations for AI-enabled medical devices	20
6.13 General ethical and regulatory challenges for the medical community	21
6.14 The UK’s sandbox for healthcare AI development	21

7. Clinical evaluations and clinical investigations.....	21
8. Staffing levels	22
8.1 Minimum staffing levels in small organisations	22
9. Post market surveillance	22
9.1 The Vigilance System.....	22
10. Device labelling and registration.....	22
10.1 EUDAMED.....	22
11. Medical device regulatory updates.....	23
11.1 EU medical device regulations	23
11.2 UK medical device regulations	23
11.3 US medical device regulations	24
11.4 An overview of the EU, UK, and US medical device markets.....	26
11.5 Regulation of SaMD in Australia.....	26
12. Product liability law.....	26
12.1 EU Product Liability Law.....	26
12.2 US Products Liability Law	27
13. Programming languages and tools.....	28
13.1 Microsoft Excel™	28
14. Standards	28
14.1 Harmonisation process	28
Book reference list	29
Chapter 1.....	29
Chapter 2.....	30
Chapter 3.....	33
Chapter 4.....	35
Chapter 5.....	35
Chapter 6.....	40
Chapter 7.....	57
Chapter 8.....	62
Chapter 9.....	63
Version history:	70

1. Introduction

As mentioned in Section 1.6 of the book, this *Supplement* is designed to be read in conjunction with the printed publication. It contains material that could not be fitted into the tight constraints of a printed publication, just missed the production deadline, or refers to documents published after the deadline (October 2023). The additional material refers to the relevant Chapter/Section in the book.

As will be evident, this document is a work-in-progress that will be periodically updated to reflect changes in regulations, standards, and guidance. Each section contains a brief summary of the referenced material, but the full text can be read by simply following the appropriate link.

The first version of this document to be made publicly available (in March 2024) was actually version 2.4. This new version (2.5) represents the first update. The main changes are referenced in the [summary](#) at the end of the document. Apart from providing useful updates on selected topics, perhaps the most practical use of the document will be the inclusion of [clickable hyperlinks](#) for all the web references given in the book, which would avoid readers having to type complex URLs into web browsers.

The structure of this document is topic-based, so different regulatory approaches (EU, UK, US) to a given issue will be covered where appropriate.

2. Risk controls

2.1. Risk control measures external to the software

[Reference in the text](#): Section 5.4.1.4 (Software safety classification)

Risk control measures (RCM) *external* to the software may include physical systems (separate hardware or software) as well as *procedures* performed by healthcare professionals that may mitigate any harm caused by the failure/malfunction of the specific medical device software under development. This relates to documented intended use and intended users. For example, diagnostic software that may assist in the diagnosis of disease X is stated not to be used as the sole means of making a diagnosis.

Other external RCMs would include systems and/or software that check the accuracy/validity of the software in the field (e.g., external audit schemes). Note that such systems are separate from any final product testing performed by the manufacturer, which is deemed internal to the software development process.

If the external RCMs are comprehensive to the point where a software failure could not conceivably result in harm to a patient, then the software can be classified as Class A and be subject to less rigorous software engineering. However, if a manufacturer relies on an RCM-based ‘safety argument’ to reduce the software safety classification he must be able to verify the effectiveness of such measures ‘in the field’.

3. Medical device software

3.1 MDCG guidance on MDSW-hardware combinations

Reference in the text: Section 6.3.4.5 (Wearable devices)

The MDCG has recently issued guidance on the qualification and conformity assessment of MDSW (mostly apps) that is intended to work with hardware or 'hardware components' (e.g., external sensors or hardware components built into smartphones).

https://health.ec.europa.eu/system/files/2023-10/md_mdcg_2023-4_software_en.pdf

It contains some useful information but has also been criticised for its lack of clarity on key regulatory questions.

<https://www.johner-institute.com/articles/regulatory-affairs/mdcg-2023-4/>

3.2 Software classification according to IEC 62304

Reference in the text: Section 5.4.1

More on software classification:

<https://www.johner-institut.de/blog/iec-62304-medizinische-software/sicherheitsklassen-iec-62304/>

This article was written in December 2017 but is still relevant. Note that some figures are in German.

For a general review ("Software and IEC 62304"):

<https://www.johner-institut.de/blog/category/iec-62304-medizinische-software/>

3.3 Coding standards

Reference in the text: Sections 5.4.4, 8.5.

Although the article below was written quite a long time ago (December 2016) it contains a concise summary of the reasons for employing coding standards to fulfil the software life cycle requirements of MDR 17/745 and reiterates many of the points made in the book.

<https://www.johner-institut.de/blog/iec-62304-medizinische-software/kodierrichtlinien-iec-62304-fda/>

3.4 "Intended use" and "Indications for use"

Reference in the text: Sections 6.3.12.1, 6.5.3.1, 6.5.8.4.

More on the difference between these two terms:

<https://www.meddeviceonline.com/doc/key-considerations-in-intended-use-and-indications-for-use-statements-for-medical-devices-0001> (14 December 2023).

3.5 In-house development of medical software

3.5.1 The Role of (UK) Clinical and Scientific Computing staff

Reference in the text: Section 2.6.2

The UK Institute of Physics and Engineering in Medicine (IPEM) has issued a Policy Statement on the *Role of Clinical and Scientific Computing in Medical Physics and Clinical Engineering*: <https://www.ipem.ac.uk/media/emvmlak/role-of-clinical-and-scientific-computing-feb-2024.pdf> (issued 21 February 2024).

It is stated (in the *Software Engineering* section) that “The need for Healthcare Scientists who can develop and maintain software used within a clinical environment is the leading driving force behind the formation of Clinical and Scientific Computing teams”. The defined software engineering roles include “Developing in-house medical device software, following best practice, for example IPEM best practice guidance [*link below*] and the standards it contains”. <https://www.ipem.ac.uk/media/vp0ewy01/ipembe-1.pdf>

3.6 Spreadsheet development and testing

3.6.1 Lessons from the financial sector?

Reference in the text: Section 5.4.5

Although the intended purpose of financial software is obviously very different to that used in the medical domain, spreadsheet guidelines developed for the finance industry cover mainly basic principles that are universally applicable.

Large finance companies undertake a considerable amount of in-house software development (mostly spreadsheets), which comprises development by dedicated IT professionals in a central IT department as well as development by ‘other staff’ in more front-line roles. The latter type is generally undertaken by talented self-taught software developers with little or no formal training, and is referred to as End-User Computing (EUC).

The acronym is somewhat ironic as EUC stands for *equipment under control* in health and safety circles. Most ‘mission critical’ applications are generally developed by the central IT team, but one large bank admitted (in 2009) to having “approximately five times the number of critical EUC applications as those that would be classified as “SOX Tier-1” applications².

² SOX refers to the Sarbanes-Oxley Act, passed by the US Congress in 2002 in response to serious fraud scandals in the financial sector in the US. The implications for spreadsheets used by large companies for financial reporting were discussed by Panko and Ordway in 2008: <https://arxiv.org/ftp/arxiv/papers/0804/0804.0797.pdf>

Regarding in-house software development, organisational parallels between large health institutions and large financial institutions are limited (central IT departments in large hospitals do *not* generally develop software, and certainly not medical software), but it is interesting to read how a large bank recognised the importance of EUC and developed policies and procedures to help ensure that it was conducted within a more controlled environment.

<https://arxiv.org/ftp/arxiv/papers/0909/0909.2455.pdf>

3.6.2 Spreadsheet testing

Reference in the text: Sections 2.2.2, 3.3.3, 5.4.5

The book discusses software engineering process techniques to reduce the probability of introducing errors into spreadsheets but it must be assumed that some errors will remain. As for any other types of software, spreadsheet testing is therefore crucial to find and eliminate these 'residual bugs'.

Panko R. Spreadsheet Errors: What We Know. What We Think We Can Do.

<https://arxiv.org/abs/0802.3457>

In the above seminal 2008 publication Ray Panko made the case that cell-by-cell code inspection is the more reliable and efficient way to uncover spreadsheet errors. In a related 2015 presentation, Panko considered what we *don't* know about spreadsheet errors, which includes discussion of relevant research on human cognition.

<https://eusprig.org/wp-content/uploads/1602.02601.pdf>

3.7 Clinical information systems

Hospital Information Systems (HIS)

Radiology Information Systems (RIS)

Laboratory Information [management] Systems (LIMS)

Patient Data Managements Systems (PDMS)

PDMS is a special case and could qualify as a medical device. For more information see:

<https://www.johner-institut.de/blog/tag/informationssysteme/>

<https://www.johner-institut.de/blog/gesundheitswesen/pdms/>

Original reports in German but your web browser will easily translate.

4. Quality management systems

4.1 Recommended eQMS tools

Reference in the text: Section 5.2 (Quality management)

A 'software vendor checklist' produced by the Greenlight Guru company may be used as the basis for an eQMS tender document:

<https://www.greenlight.guru/downloads/qms-software-vendor-checklist>

4.2 Quality manual template

Reference in the text: Sections 5.2.1.2, 5.2.1.5, 5.2.2.

For those starting from scratch with formal QMS, a useful free template is available from Greenlight Guru:

<https://www.greenlight.guru/downloads/quality-manual-template>

4.3 FDA formalises the move from QSR to QMSR

Reference in the text: Sections 6.5.6, 9.2.1.3

The FDA has published its 'final rule' amending the Quality System Regulation (QSR) to better align with ISO 13485:2016. The title of 21 CFR Part 820 will change from QSR to Quality Management System Regulation (QMSR). The enforcement date for compliance with the new regulation is 2 February 2026:

<https://www.greenlight.guru/blog/fda-qmsr-final-rule>

5. Cybersecurity

5.1 Legacy devices

Reference in the text: Sections 6.3.6.7, 6.5.8.1; Chapter 8

There is recent guidance from the MITRE Corporation³ about managing cybersecurity risks for "legacy devices". MITRE is a not-for-profit organisation that performs research for the FDA and other US government agencies. Its guidance may be regarded as complimentary to established IMDRF guidance as it is more focused on the end-user. The guidance applies to managing medical devices that were not originally designed according to modern cybersecurity principles.

<https://www.mitre.org/sites/default/files/2023-11/PR-23-3695-Managing-Legacy-Medical-Device%20Cybersecurity-Risks.pdf> (November 2023).

³ MITRE is not an acronym, but the name given by one of the founders of the company in the 1950s.

<https://www.imdrf.org/sites/default/files/2022-05/IMDRF%20Cybersecurity%20proposed%20document%20PDF.pdf> (May 2022)

5.2 Finalised FDA cybersecurity guidance 2023

Reference in the text: Section 6.5.8.11

In September 2023 the FDA finalised its guidance on cybersecurity of medical devices⁴. The guidance is similar to the April 2022 draft, but it provides more detail on conducting cybersecurity risk assessments, interoperability considerations, and documents to be included in premarket submissions.

<https://www.fda.gov/media/119933/download> (27 September 2023).

A gap assessment checklist has been developed by Greenlight Guru to help in the implementation of the new (2023) FDA guidelines on medical device cybersecurity:

<https://www.greenlight.guru/downloads/cybersecurity-gap-assessment-checklist>

The final guidance also rests on a new statutory authority explicitly authorizing the FDA to (a) require cybersecurity information be included in medical device submissions for “cyber devices” and (b) require manufacturers to take actions to demonstrate reasonable assurance that such devices and related systems are “cybersecure.”

<https://www.ropesgray.com/en/insights/alerts/2023/10/fda-finalizes-guidance-on-medical-device-manufacturer-cybersecurity-responsibilities>

<https://www.meddeviceonline.com/doc/understanding-the-fda-s-new-medical-device-cybersecurity-guidelines-0001>

5.3 CISA’s strategic plan

The Health Sector Coordination Council (HSCC) of the US Cybersecurity and Infrastructure Security Agency (CISA) has published a revised 5-year strategic plan (2024-2029).

<https://healthsectorcouncil.org/JSP2>

It is suggested that manufacturers may use this document to compliment IEC 81001-5-1 and, as such, it may have a bearing on what is considered "state of the art" for the IT security of health-related equipment, including medical devices.

<https://25622905.hs-sites-eu1.com/how-important-the-regulatory-overview-is>

The plan represents a huge collaborative effort of over 400 organisations (US healthcare providers and pharmaceutical/medtech companies) and several government agencies, including the FDA. It is therefore likely that the revised plan will influence future FDA guidance on cybersecurity of medical devices. It may also influence future MDCG cybersecurity guidance (ref: EU MDR) as the current document is rapidly becoming outdated.

⁴ FDA concerns about cybersecurity issues associated with medical devices all started with the 2017 WannaCry ransomware attack (see Section 8.1 of the book).

5.4 Software Bill of Materials

Reference in the text: Sections 6.3.6.7, 6.5.8.11, 8.1, 8.2.5, 8.5.1

As explained in the book, the Software Bill of Materials (SBOM) plays an important role in the management of cybersecurity vulnerabilities. The link below contains information on SBOMs in relation to regulatory requirements and common data formats:

<https://www.johner-institut.de/blog/iec-62304-medizinische-software/sbom-software-bills-of-materials/>

It is pointed out in the Johner Institute article that MDR 17/745 does not *specifically* require a SBOM (Annex I, Section 17.2), but does require IT security according to the ‘state of the art’. SBOMs *are* the state-of-the-art, QED.

In contrast, SBOMs are a specific FDA requirement in the US, as described in ‘Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions’, September 2023 (see [Section 5.2](#)).

5.4.1 Use of SBOMs

OK, you have produced an accurate SBOM, now what do you do with it? Essentially, the SBOM acts as the *input* to the wider process of identifying cybersecurity vulnerabilities. Each software component in the SBOM inventory must be checked for possible threats using a national/international cybersecurity database and appropriate action taken (usually in the form of a security patch) if the matching process uncovers potential issues.

In the US, the national repository is the National Vulnerability Database (NVD). To make the matching process manageable, an SBOM with numerous entries must somehow be integrated into the organisation’s vulnerability management process (as described in its cybersecurity policy).

<https://nvd.nist.gov/>

<https://www.crowdstrike.com/cybersecurity-101/secops/software-bill-of-materials-sbom/>

The cybersecurity policy is particularly important here because there must be a documented means of prioritising the actions for resolution of the identified vulnerabilities (there could be many!); a process typically based on assigned severity (look up CBSS score), perceived risk, exploitability, and ease of fix. Clearly, if an available security patch could fix several identified security issues, then that would get priority. The NVD uses the common vulnerability scoring system (CVSS) to represent the severity of an information security vulnerability. A score on a scale of 0-10 is assigned for all published common vulnerability and exposures (CVE) records:

CVSS v3.x Ratings

Severity	CVSS score
None	0.0

Low	0.1 - 3.9
Medium	4.0 - 6.9
High	7.0 - 8.9
Critical	9.0 - 10.0

The CVSS is not a measure of risk, which should be assessed separately.

<https://nvd.nist.gov/vuln-metrics/cvss>

<https://www.balbix.com/insights/understanding-cvss-scores/>

The CVSS is a useful severity measure but does not tell you how exploitable (by hackers) a particular vulnerability might be. The NVD promotes the use of a semi-quantitative scoring system to assess exploitability of a particular vulnerability (i.e., the Exploit Prediction Scoring System, EPSS) to further assist a medical device manufacturer in prioritising actions. The EPSS is effectively a probability measure so the metric scale is 0-100%.

<https://www.bringa.com/glossary/what-is-epss-score/>

The US Cybersecurity and Infrastructure Security Agency (CISA) maintains a up to date list of cybersecurity vulnerabilities that are *known* to have exploited by cybercriminals 'in the wild'. This known exploited vulnerabilities (KEV) repository is known as the 'CISA KEV list'.

Although there is no prescribed best practice method for prioritising actions for a list of identified vulnerabilities, it is reasonable to suggest that an algorithm/filter of the following nature might be used.

IF (CVSS > x . AND/OR EPSS > y . OR present on the CISA KEV list), THEN DO P

Where P is an urgent remedial action.

Clearly, even if a vulnerability has an CVSS of 8.0 but an EPSS of 0% (i.e. not yet exploited in the field so not on CISA KEV list) then it would generally be considered low priority for urgent action. The general approach must be tempered by a risk assessment that considers the likelihood that a vulnerability having a high CVSS *and* a high EPSS could cause harm to a patient (directly or indirectly) if the vulnerability was exploited to the extent that affected device functions were compromised.

5.4.2 EU cybersecurity vulnerabilities databases

A recent (January 2023) update to the Network and Information Security (NIS2) Directive tasked the European Agency for Cybersecurity (ENISA) with establishing and maintaining an EU cybersecurity vulnerability database.

Although the Agency is still establishing the policies and procedures around this database to ensure its security and integrity, the EC is favouring a decentralised system whereby manufacturers disclose vulnerabilities to the National Computer Security Incident Response Team (CSIRT) in the country in which they are based.

<https://therecord.media/eu-rejects-requirements-for-manufacturers>

The EU Cybersecurity Resilience Act (CRA), which codifies the above reporting system (amongst other duties of manufacturers) is set to become law in the EU in April 2024.

<https://digital-strategy.ec.europa.eu/en/policies/cyber-resilience-act>

<https://www.insideprivacy.com/cybersecurity-2/the-cyber-resilience-act-is-one-step-closer-to-becoming-law/>

5.5 EU Cybersecurity Resilience Act

Reference in the text: Section 6.3.6.7.

The EU Cybersecurity Resilience Act (CRA) is in active development and is due to become law in 2026 or 2027.

<https://spyro-soft.com/blog/cybersecurity/the-cybersecurity-resilience-act-cra>

In principle, the CRA will apply to “all products with digital elements”, but a limited number of product categories that are already considered to be sufficiently regulated (*including* medical devices, automotive vehicles and aviation products) will be exempt from the regulations.

<https://www.fieldfisher.com/en/insights/update-on-the-eu-cyber-resilience-act-for-uk-companies#>

6. Artificial intelligence/machine learning

6.1 EU AI Act

6.1.1 The legal process

Reference in the text: Sections 7.2.3, 9.3.3.

The EU AI Act has now been unanimously endorsed by the 27 member states, thus affirming the political agreement reached in December 2023. The Act faced technical revisions for over a month due to its complexity, but remaining concerns were finally resolved upon the adoption of the AI Act by the Committee of Permanent Representatives on 2 February 2024.

The 27 member states approved the legislation on May 21, 2024, so that it can come into force after publication in the Official Journal of the EU and a further 20-day period. The EU AI Act was finally published in the Official Journal of the EU on 12 July 2024 and came into force on 1 August 2024. https://eur-lex.europa.eu/legal-content/DE/TXT/?uri=OJ:L_202401689

However, various transition periods are allowed for manufacturers to get fully up to speed with the new regulations:

February 2025: Regulations on prohibited AI systems become applicable.

- August 2025: Obligations for General Purpose AI (GPAI) systems become applicable, excluding fines.
- August 2026: All provisions of the AI Regulation apply, except for Article 6 paragraph 1 AI Regulation (classification rule for high-risk AI systems according to Annex I)

The Act called for the establishment of a **European AI Office**, which came into force on 21 February 2024. The tasks specified for the institution include:

- Developing tools for assessing the capabilities of general-purpose AI models.
- Monitoring the implementation of the new rules.
- Identifying emerging risks, investigating potential infringements, and supporting the enforcement of regulations on prohibited AI practices and high-risk systems.

The AI office will collaborate with relevant bodies under sectoral legislation, facilitate information exchange between national authorities, and maintain databases of when general-purpose AI models are integrated into high-risk AI systems.

6.1.2 Definitions

[Reference in the text](#): Sections 7.2.3, 9.5.5.1.

The EU AI Act is now available in an almost 900-page document that is somewhat difficult to read. In particular, there has been some concern regarding the new definition of "AI system":

"An AI system is a machine-based system designed to operate with varying levels of autonomy and that may exhibit adaptiveness after deployment and that, for explicit or implicit objectives, infers, from the input it receives, how to generate outputs such as predictions, content, recommendations, or decisions that can influence physical or virtual environments."

The final version of the AI Act contains a more specific qualification of medical devices as "high risk AI". Namely, AI-enabled medical devices are considered high risk if:

- (i) they are intended to be used as a safety component of a product, or if they themselves are a product covered by the Medical Device Regulation (EU) 2017/745 (MDR) or by the In Vitro Diagnostic Regulation (EU) 2017/746 (IVDR) **and**
- (ii) the relevant product is required to undergo a third-party conformity assessment pursuant to the MDR or the IVDR. This does also apply if the AI system is placed on the market or put into service independently from the relevant product.

As the vast majority of AI systems used in medical devices fulfil these conditions, most AI systems applied in medical devices would be categorized as "high-risk" under the EU AI Act. <https://www.allenoverly.com/en-gb/global/blogs/tech-talk/what-are-the-legal-implications-of-european-ai-regulations-for-medical-device-companies>

<https://www.taylorwessing.com/en/insights-and-events/insights/2023/09/medical-devices>

6.1.3 General content

[Reference in the text](#): Sections 7.2.3, 9.5.5

Compliance is required by all providers, distributors or deployers of AI systems and models within the EU or marketed into it. The degree of regulation is risk dependent, with four levels ranging minimal to unacceptable. Special obligations apply to generative and general-purpose AI depending on whether the model is open source or not.

The following guidance document offers three use cases to illustrate compliance considerations: 1) spam filters as low-risk, 2) artistic deep fakes as low-risk with disclosure requirements, and 3) credit scoring as high-risk requiring stringent compliance due to potential discrimination.

<https://media.francedigitale.org/app/uploads/prod/2024/02/01162803/Compliance-AI-Act-Feb-24.pdf> (February 2024).

6.1.4 Implications for medical device manufacturers

The Johner Institute has produced a useful summary of the implications of the EU AI Act for medical device manufacturers:

<https://www.johner-institute.com/articles/regulatory-affairs/and-more/eu-data-act-cards-on-the-table/> (30 November 2023)

One of the important things highlighted in the article is that the controversial data-sharing requirements described in Chapter II of the Act do not apply to micro or small enterprises. According to EU Recommendation 2003/361/EC, these are enterprises that employ fewer than 50 persons and whose annual turnover and/or annual balance sheet total does not exceed EUR 10 million.

Following the final approval of the EU AI Act, work is now underway to produce guidelines for its adoption, including the medical devices sector. Watch this space!

6.1.5 The position of open-source AI

The position of open-source software was a contentious issue in the drafting of the new regulations, some feeling that the general approach to open source was too relaxed (AI Act Newsletter, 30 April 2024), while others held a different view. The situation was not helped by the inclusion of a serious error in the originally published draft regulations, which indicated that true open-source AI would not be exempt from the provisions of the Act – exactly the opposite of what was originally intended.

The history of how the EU AI Act was developed, with particular reference to open source has been usefully documented by the Open Future Group:

<https://openfuture.eu/observatory/aia-open-source/>

In the end, the regulations contain a limited exemption for open-source software, depending on whether it is contained in an AI system or a General-Purpose AI Model:

<https://www.orrick.com/en/Insights/2024/05/The-EU-AI-Act-Open-Source-Exceptions-and-Considerations-for-Your-AI-Strategy#>

As the exemption for open-source will *not* generally apply if the software is incorporated into “high risk systems”, manufacturers of complex software-based medical devices may not be able to make use of the exemption. Further clarification from EU medical devices regulators is awaited.

6.1.6 Codes of Practice

Reference in the text: None

See EU AI Act Newsletter 56, 08/07/24

Article 56 of the Act establishes Codes of Practice as a temporary means compliance for GPAI model providers. These codes are intended to bridge the gap between the point at which provider obligations take effect and when formal standards are adopted (3+ years later). While voluntary, adhering to these codes presumes conformity with Articles 53 and 55 obligations. Providers not following the codes must prove compliance by other means.

On an indirectly related issue, note that the adoption deadline for most of the *harmonised* standards required for the *EU MDR* have been put back until May 2028 (see 14.1).

6.2 Diagnostic Assistance Levels (DALs)

Reference in the text: None.

The article below (from authors in Japan) contains a proposal for a risk-based classification system for AI-based computer-aided diagnosis software used in radiology. The proposed system has 5 levels (DL1 to DL5) and is perhaps something that the IMDRF may consider in due course. The adoption of such a system would avoid the majority of AI-enabled medical devices being classified as “high risk” under the new EU AI Act (see 6.1.2).

https://www.jstage.jst.go.jp/article/abe/7/0/7_7_118/article/-char/en (2018)

6.3 Data quality

Reference in the text: Section 9.5.5.2

The EU Data Act was passed in early December 2023.

<https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=COM%3A2022%3A68%3AFIN>

One of its goals is to promote economic growth through improved availability of data, but that requires interoperability and the willingness to share this data. The ways in which the EU Data Act may affect medical device manufacturers are discussed in the article below:

<https://www.johner-institut.de/blog/regulatory-affairs/eu-data-act/> (5 February 2024)

6.4 FDA's Predetermined Change Control Programme (PCCP)

Reference in the text: Section 6.5.8.9 (Devices containing AI technology)

Regarding post-market changes, a series of recent articles in *Med Device Online* provide further detail on what the FDA will expect from manufacturers of AI-based medical devices in the context of its PCCP.

Part 1: <https://www.meddeviceonline.com/doc/medical-device-postmarket-change-controls-fda-k-software-modification-guidance-0001>

Part 2: <https://www.meddeviceonline.com/doc/deciphering-new-u-s-laws-around-predetermined-change-control-plans-0001>

Part 3: <https://www.meddeviceonline.com/doc/samd-pccp-implementation-beyond-ai-ml-considerations-challenges-0001>

Although the FDA consider PCCP to be the way forward for dealing with AI/ML-enabled medical devices, the legal position was, until recently, unclear. However, since March 2023 the FDA now has *statutory authority* to consider PCCP in its review of all device submissions. On December 29, 2022 Section 3308 of the Appropriations Bill of 2023 amended the Food, Drug & Cosmetic Act (FD&C) to include Section 515C ("Predetermined Change Control Plans for Devices"), which authorizes the FDA to consider PCCPs while reviewing submissions under PMA, PMA supplement or 510(k). The amendment to the Act became law on March 29, 2023, along with the amendment in Section 524B focused on the cybersecurity of medical devices.

The amendment means that a device *subsequently modified* according to an established PCCP may not be used as a predicate for future (510(k)) submissions. In other words, only the version of the device cleared or approved *before* any changes made under the PCCP may be used by a sponsor as a predicate device.

6.5. Foundation models

Reference in the text: the term 'foundation model' is not used in the text, but related issues are covered in the AI sections of Chapters 6 and 9.

Foundation models represent the 'next wave' of AI technology and may replace the task-specific models that have been developed over the last 5 years. They are so-called because their design means that they can be as the foundation for many applications of the basic model with minimal fine tuning. Examples include GPT-4 and BERT. Such systems can generate

a coherent output (e.g. an essay or graphic) from a short prompt, even if the model was not specifically trained on how to generate the text/image etc. in that way.

Rishi Bommasani, the Society Lead at the Stanford Center for Research on Foundation Models, has suggested a tiered approach to the categorisation of foundation models that may lead to proportionate regulation. This is relevant in the context of the EU AI Act (Section 6.1).

<https://crfm.stanford.edu/2023/11/18/tiers.html> (2021).

The complex legal issues surrounding foundation models and ‘general-purpose AI’ (GPAI) – also known as ‘artificial general intelligence’ (AGI) (see Section 9.5.5.1 of the book) are considered in the context of the EU AI Act in the article below:

<https://ai-regulation.com/regulating-foundation-models-in-the-ai-act-from-high-to-systemic-risk> (January 2024).

6.6 Machine Learning Good Practice (MLGP) Guidelines

Reference in the text: Sections 3.3.4, 9.5.5.

10 basic principles of MLGP have been identified in joint statement from the US FDA, the UK MHRA and Health Canada, which was published in 2021:

<https://www.fda.gov/medical-devices/software-medical-device-samd/good-machine-learning-practice-medical-device-development-guiding-principles>

The links below provide brief commentaries on the above guidance.

<https://www.meddeviceonline.com/doc/ml-powered-medical-devices-tips-for-regulatory-compliance-0001>

<https://www.meddeviceonline.com/doc/the-guiding-principles-of-gmlp-identified-by-the-fda-hc-and-mhra-0001>

The FDA issued an updated document in June 2024 that is generally more detailed and particularly elaborates on principles 7 and 9 from the first document.

<https://www.fda.gov/medical-devices/software-medical-device-samd/transparency-machine-learning-enabled-medical-devices-guiding-principles>

The IMDRF has recently (June 2024) issued its own *draft* guidelines for the use of ML for medical device development that is word-for-word identical to the 10 principles issued by the FDA/Health Canada/UK MHRA in 2021.

<https://www.imdrf.org/consultations/good-machine-learning-practice-medical-device-development-guiding-principles>

Bizarrely, there is no reference to the above 2021 FDA publication in the IMDRF document. I do not understand this. The closing date for comments on the draft is 30 August 2024.

6.7 Regulatory issues with generic LLMs

Reference in the text: Section 9.5.5

LLM: Large language model.

Commonly used Generic chatbots include OpenAI's ChatGPT, Google's Gemini, and Microsoft's Copilot (formally Bing Chat).

6.7.1 Is ChatGPT a medical device?

A German law firm has claimed that ChatGPT should be considered a medical device and has sought clarification from the German regulator.

<https://e-health-com.de/details-news/vorberglaw-fordert-regulatorische-klarheit-fuer-chatgpt-im-bereich-digitaler-medizinprodukte/> (7 November 2023).

This was highlighted in a *Medical Device Briefing* (Issue 38/23) published by the Johner Institute on 28 November 2023, in which the claim was disputed, based on the intended purpose of ChatGPT. According to its Terms of Use, OpenAI does not intend its products to be used for medical diagnostic or therapeutic purposes:

*"You must not use any output relating to a person for any purpose that could have a legal or material impact on that person, such as making credit, educational, employment, housing, insurance, legal, **medical**, or other important decisions about them".*

<https://openai.com/policies/terms-of-use> (31 January 2024)

6.7.2 Using LLM-based chatbots (such as ChatGPT) in accordance with Data Protection

Regulations:

A good summary of this topic can be found here:

<https://datenschutz-hamburg.de/news/checkliste-zum-einsatz-llm-basierter-chatbots>

6.7.3 Using generative AI technology for interrogating international standards

In principle, generic or more specific AI tools may be used to search for answers to specific questions about international standards. The more specific tools tend to be a combination of a proprietary knowledge base (built by the company marketing it) and an LLM. The argument for dedicated system is that the data going into them is much more carefully vetted than the tens of millions of data items (trawled from the general internet in a *relatively* uncontrolled fashion) being input to generic ("ask me anything") systems such as ChatGPT. Better data in, better answers out, to put in simply. The 'rub', of course, is that general tools such as Gemini and ChatGPT are free to use; proprietary tools are not. For example, Advisera has developed a generative AI tool for extracting information from some of the main ISO management standards: <https://advisera.com/experta/>

6.7.4 Regulatory issues and controversies surrounding LLMs used in healthcare

[Reference in the text](#): Sections 6.3.6.5 (EU), 6.4.4.3 (UK), 6.5.8.9 (US), 9.5.5.5

A comprehensive review of what was referred to as the “regulatory ambiguity” of generic LLMs applied in the healthcare field was published (as Viewpoint article) in *The Lancet* in September 2024:

Freyer O, et al. A future role for health applications of large language models depends on regulators enforcing safety standards. *The Lancet Digital Health*, 6: 9: E662-672, September 2024.

[https://www.thelancet.com/journals/landig/article/PIIS2589-7500\(24\)00124-9/fulltext](https://www.thelancet.com/journals/landig/article/PIIS2589-7500(24)00124-9/fulltext)

6.8 AI in Medical Physics - Roles and responsibilities of medical physicists

[Reference in the text](#): Section 2.6.1

The International Atomic Energy Agency (IAEA) has recently published a guidance document on “Artificial Intelligence in Medical Physics - Roles, Responsibilities, Education and Training of Clinically Qualified Medical Physicists”.

<https://www.iaea.org/publications/15450/artificial-intelligence-in-medical-physics> (2023).

6.9 Notified Bodies Guidelines on AI (5th edition).

[Reference in the text](#): Section 6.3.6.5

Created by the German Notified Bodies Alliance (IG-NB), this document takes the form of a checklist for use by EU Notified Bodies and other interested parties. Version 5 was published on 15 December 2023.

https://www.ig-nb.de/?tx_epxelo_file%5bid%5d=1003235&cHash=f03bcf63e76d99d4ca5b51957cff7f69

Crucially, each question contains a reference to a clause in a standard indicating how the requirement might be achieved. The checklist/questionnaire is based, in part, on the “Guideline for AI for Medical Devices” by Johner, Molnar et al [see [Reference List](#), Chapter 6, ref 33].

6.10 Validation standards for the application of AI within a healthcare setting

[Reference in the text](#): Section 9.3.3

There is a new British Standard that is being adopted/encouraged within some UK clinical departments, either as a development guide or, in a procurement setting, as a specification that potential commercial suppliers would be required to comply with. The standard comprises a set of auditable clauses so can be used to conduct conformity audits leading to certification.

<https://knowledge.bsigroup.com/products/validation-framework-for-the-use-of-artificial-intelligence-ai-within-healthcare-specification?version=standard>

The standard takes a top-level view of the term *validation*, providing a set of requirements for ‘key evaluation criteria’ such as clinical benefits, standards of performance, successful and safe integration into the clinical work environment, ethical considerations, and socially equitable outcomes from system use.

6.11 Standards to support the development of AI-enabled medical devices

Two standards are being developed to guide how *risk management* techniques should be applied to AI-enabled medical devices:

ISO 23894:2023: Information technology – Artificial intelligence – Guidance on risk management. (*This is a generic standard based on ISO 31000:2018*)

BSI AAMI 34971:2023: Application of ISO 14971 to machine learning in artificial intelligence.

In connection with the new EU AI Act, CEN/CENELEC is busy working on a wide range of standards that will support its implementation. The European Trade Union Organisation (ETUC) publishes a newsletter containing updates and progress reports from the various working groups.

https://etuc.org/sites/default/files/page/file/2024-05/AI%20standardisation%20Inclusiveness_Newsletter3.pdf

6.12 Product liability considerations for AI-enabled medical devices

[Reference in the text](#): Section 7.3.2

<https://www.meddeviceonline.com/doc/product-liability-considerations-for-ai-enabled-medtech-0001>

The above article is written by US lawyers from the perspective of avoiding and defending product liability claims. Some definitions relate specifically to US law, but the general principles are equally applicable to EU Product Liability Laws.

In September 2022, the EC published a *proposal* for a Directive on AI Liability, on the basis that “Current national liability rules, in particular based on fault, are not suited to handling liability claims for damage caused by AI-enabled products and service”. The Directive itself has not appeared yet, but the proposal can be read here:

https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX%3A52022PC0496&utm_campaign

6.13 General ethical and regulatory challenges for the medical community

Reference in the text: 6.4.4.3

Viewpoint article (April 2024): Ethical and regulatory challenges of large language models in medicine:

[https://www.thelancet.com/journals/landig/article/PIIS2589-7500\(24\)00061-X](https://www.thelancet.com/journals/landig/article/PIIS2589-7500(24)00061-X)

Editorial (August 2024): Balancing AI Innovation with patient safety:

[https://www.thelancet.com/journals/landig/article/PIIS2589-7500\(24\)00175-4/fulltext](https://www.thelancet.com/journals/landig/article/PIIS2589-7500(24)00175-4/fulltext)

The above Editorial calls on the UK government to urgently introduce “comprehensive AI regulations tailored to the health-care sector”.

6.14 The UK’s sandbox for healthcare AI development

Reference in the text: Section 6.4.4.3

The MHRA has recently announced the establishment of a regulatory sandbox project, referred to as the “AI Airlock”, which started in pilot form in May 2024.

<https://www.gov.uk/government/collections/ai-airlock-the-regulatory-sandbox-for-aiamd>

Its aim is to provide a “safe space” to trial innovative healthcare AI products before they are formally implemented. Its main distinguishing feature is the plan to involve *all* interested parties. A stated aim is to further clarify the distinction between AI as a *medical device* (AlaMD) and other health technologies that use AI. The phrases *Digital Medical Devices* and *Digital Health Products* and have also started to appear in the literature:

<https://www.meddeviceonline.com/doc/the-ai-medical-devices-revolution-unlimited-potential-amid-regulatory-challenges-0001>

7. Clinical evaluations and clinical investigations

Reference in the text: Sections 6.3.10, 6.5.5

This article provides a brief summary of the main regulatory (FDA, EU) requirements for clinical evaluations and clinical investigations, with reference to relevant standards. The website referenced below also contains access to the output from the Q&A session at the associated webinar held in 2023.

<https://www.greenlight.guru/blog/navigating-clinical-evaluations-and-investigations-in-medtech> (12 January 2024)

8. Staffing levels

8.1 Minimum staffing levels in small organisations

Reference in the text: Sections 2.6.2, 2.7; Chapter 2: Appendix1, Section 6.3.7.1.2.

There is a famous *US Navy Seal* saying: “Two is one and one is none”, which applies to small combat teams.

<https://preparednesshub.com/two-is-one-and-one-is-none-the-art-of-redundancy/>

The idea simply means that only having one of something is *effectively* the same as not having it at all, and having two of something is the same as what you think having one means. It applies equally well to small teams working in industry and commerce, including lone programmers working in clinical departments. The saying is referred to in a Greenlight Guru paper on managing design controls using spreadsheets, which discusses the concept of a single point of failure, and the desirable feature of built-in redundancy.

<https://www.greenlight.guru/blog/managing-design-controls-on-spreadsheets>

9. Post market surveillance

9.1 The Vigilance System

Reference in the text: Sections 6.3.8, 6.3.14.2, 6.3.15

The MDCG has updated its published guidance on the vigilance system for CE marked medical devices. That is, the system for reporting adverse incidents to the relevant authorities. It also covers routine periodic reports that are required under MDR 17/745.

https://health.ec.europa.eu/document/download/dbd0d748-d646-4274-afaa-399952809389_en?filename=mdcg_2024-1_en.pdf (January 2024).

A template form (compliant with the EU MDR) for the reporting serious adverse incidents can be downloaded from:

<https://info.advisera.com/13485academy/free-download/manufacturer-incident-report-for-serious-incidents-and-incidents/> (February 2024)

10. Device labelling and registration

10.1 EUDAMED

Reference in the text: Section 6.3.14.2

The development of the EUDAMED database continues to grind on 7 years after the publication of EU MDR regulations that made it a key requirement. There is now (July 2024) a new draft for the roll out of EUDAMED that pushes the final implementation date back to 2027.

https://health.ec.europa.eu/document/download/04ce2012-97df-4dd0-8a39-d4f6993b9e16_en?filename=md_eudamed_roadmap_en.pdf

11. Medical device regulatory updates

11.1 EU medical device regulations

11.1.1 General issues and industry response

Reference in the text: Section 6.3

The following MedTech Europe “position paper” is undated but assumed to be published in October or November 2023.

https://www.medtecheurope.org/wp-content/uploads/2023/11/medtech-europe_future-of-medical-technology-regulations_position-paper_2023.pdf

The report is critical of the EU regulatory system and identifies what it perceives as several fundamental problems associated with lack of transparency and inconsistent application of the rules by Notified Bodies. Several solutions to the perceived problems are proposed.

Commenting in support of the MedTech Europe position, other interested parties have proposed that the regulatory scientists model the effects of proposed changes in legislation prior to their introduction, in a similar way to how the FDA runs pilot schemes [Johner Institute Journal, 40/23, 28 November 2023].

11.1.2 Transition arrangements from MDD to MDR

Reference in the text: Section 6.3.1.1

Confirmation of the new transition deadlines, plus more detail on the background and rationale can be found here:

<https://advisera.com/articles/deadlines-for-medical-device-manufacturers-to-transition-from-mdd-to-mdr/>

11.2 UK medical device regulations

Reference in the text: Section 6.4

11.2.1 MHRA guidance

The MHRA is due to update its guidance on *Managing Medical Devices* in the first half of 2024. The revision will be based on the 2022 consultation process but is bound to continue to refer to the current 2002 UK Medical Device Regulations. The existing guidance can be found here: <https://www.gov.uk/government/publications/managing-medical-devices>

New “All new” UK medical device regulations are not now expected until July 2025.

11.2.2 Draft Statutory Instrument to amend the post market surveillance (PMS) requirements of the UK Medical Devices Regulations 2002.

[Reference in the text](#): Section 9.4.1

In July 2023 the UK government published a [draft statutory instrument](#) on the World Health Organisation website to amend the Medical Devices Regulations 2002. This draft legislation is limited, aiming (only) to insert new post-market surveillance (PMS) requirements for medical devices placed on the market in Great Britain (GB). If passed by Parliament, it is expected that this legislation will come into force in mid-2024.

The publication of this draft statutory instrument follows the 2021 MHRA consultation on the future regulation of medical devices in the UK and is part of the much wider revamp of the UK's medical device regulatory framework following Brexit. It should therefore be seen as an interim measure pending the complete replacement of the UK MDR 2002 in 2025. Medical devices placed on the market in Northern Ireland will continue to be subject to the EU regulatory framework under the Northern Ireland Protocol.

The requirements in the proposed UK PMS regulations closely resemble those already established in the EU Medical Device Regulation 2017/745, but there are some differences in the definition of some terms as well as associated requirements. The main differences - and the implications for medical device manufacturers - are summarised in the web page below: <https://www.taylorwessing.com/en/insights-and-events/insights/2023/09/updated-post-market-surveillance-rules-for-medical-devices-in-the-uk> (accessed 21/02/2024)

The *existing* arrangements (as of February 2024) for post-market surveillance of medical devices placed on the UK market are summarised in the guidance below: <https://www.digitalregulations.innovation.nhs.uk/developers-guidance/all-developers-guidance/post-market-surveillance-medical-devices/> (accessed 21/02/2024)

11.2.3 Definition of Health Institution

[Reference in the text](#): Sections 6.3.11, 6.4.6.

One of the things eagerly awaited by clinical scientists and engineers working in the NHS is what the above revised MHRA guidance has to say about the so-called health institution exemption (HIE). Prompted by the publication of MDCG guidance on the HIE under Article 5.5 of EU MDR 17/745 [see link below], the question of definition of a “health institution” has been recently debated in IPEM forums.

https://health.ec.europa.eu/system/files/2023-01/mdcg_2023-1_en.pdf (January 2023).

11.3 US medical device regulations

11.3.1 Recognised consensus standards

Reference in the text: Sections 5.1, 6.5.7

The FDA has pulled together all the information about recognised consensus standards into one database, which is called “List 61”. It includes new standards and new versions of recognized standards, as well as revisions to some standards’ extent of recognition.

<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/results.cfm>

A significant new addition is *ANSI/AAMI SW96:2023 Standard for Medical Device Security – Security Risk Management for Device Manufacturers*, which focuses on medical device security (see [Section 6.5.8.11](#) and [Chapter 8](#) of the book). The standard addresses cybersecurity risks, aligns with international risk management standards, and provides guidance for manufacturers in managing cybersecurity risks in device design.

11.3.2 Risk assessment related to device usability

Reference in the text: Sections 6.5.8.10

Usability engineering (UE) – or human factors engineering (HFE) as the FDA calls it – is the process of identifying and mitigating identified risks associated with usability. The subject is comprehensively covered in the book, but the regulatory agencies are constantly refining their approaches.

The latest draft guidance from the FDA concerns what it calls *use-related risk analysis* (URRA) and is primarily aimed at developers of drugs, biological products and combination products. The latter, of course, include medical devices but the general principles contained in the draft guidance can also be applied to pure medical devices.

<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/purpose-and-content-use-related-risk-analyses-drugs-biological-products-and-combination-products>

The draft guidance does not refer specifically to the main international standard (IEC 62366) but does refer to its own previous (2016) guidance on *Applying Human Factors and Usability Engineering to Medical Devices*.

The URRA essentially a tool to help ensure that all the possible risks associated with usability are identified early in the design process. There are clearly some gaps in the draft guidance, most of which have been identified by Moon and Matthew in their recent review:

<https://www.meddeviceonline.com/doc/fda-issues-draft-guidance-on-use-related-risk-analysis-urra-0001>

The closing date for public comments ended on 9 September 2024, so a final version is expected sometime in 2025. In the meantime, medical device manufacturers in the US are advised to continue with their existing procedures.

11.4 An overview of the EU, UK, and US medical device markets

Reference in the text: Section 6.2

The following article offers advice to medical device manufacturers on which medical device market to enter first (EU or US).

<https://www.meddeviceonline.com/doc/the-u-s-eu-or-u-k-which-medical-device-market-should-i-enter-first-0001> (published 6 November 2023)

11.5 Regulation of SaMD in Australia

Reference in the text: Section 6.3.4.6.

Passing reference was made in the book to Australian SaMD regulation in the context of clinical decision support (CDS) software. However, the regulations produced by the Therapeutic Goods Administration (TGA) cover the whole range of medical software, including SaMD.

<https://www.meddeviceonline.com/doc/understanding-australia-s-regulatory-framework-for-samd-0001>

12. Product liability law

12.1 EU Product Liability Law

Reference in the text: Sections 7.2, 7.2.2.

Latest updates are generally linked to this article about how EU product liability law affects medical device manufacturers:

<https://www.johner-institut.de/blog/regulatory-affairs/produkthaftung/>

The new EU Product Liability Directive (2024/2583) was published in the EU Official Journal on 18 November 2024. It will replace Directive 85/374/EEC. As a Directive, member states have 2 years to transpose the legislation into national law. The new laws will therefore only apply to products placed on the market or put into service after that transition period expires (i.e. November 2026). Until then, the existing PLD will continue to apply.

In brief, the new Directive will make it easier and simpler for a claimant to gain compensation for damages due to a faulty product, by expanding the definitions of key terms ('defective', 'damage' and 'product') and extending the range of individuals in the supply chain who may be held liable.

Embedded and standalone software (including AI software) is specifically included in the new definition of a product, the only exception being free and open-source software.

For more information, see:

https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:L_202402853

<https://www.twobirds.com/en/insights/2024/germany/update-reform-der-produkthaftung-beschlossen>

<https://www.cov.com/en/news-and-insights/insights/2024/10/what-can-you-expect-from-the-new-product-liability-directive>

12.2 US Products Liability Law

Reference in the text: Section 7.3.2

Notwithstanding the legal argument about whether medical software constitutes a “product”, there is a legal principle (applicable in most US states) known as the “learned intermediary doctrine” that may insulate the manufacturer of medical products (drugs or devices) from product liability claims.

In brief, provided that the manufacturer supplied adequate accompanying written information on the drug/device (including warnings about any risks) to the treating physician (i.e., the “learned intermediary”), any *subsequent* treatment decisions made by the physician “breaks the line of causation” [of harm] between the manufacturer and the patient. In several specific cases (usually involving potentially harmful drug side effects that were not explained to the patient by the prescribing doctor) US courts have generally held that the “buck stops with the physician”.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173549/>

Clearly, there must be defined ‘supply chain’ ending with a specific prescribing decision by a learned medical professional. In the context of medical devices, the doctrine would probably only apply to small treatment devices prescribed for individual use (CPAP⁵ machine, 24hr ECG monitor, etc.). It is unclear if or how this doctrine might apply to ‘mass-use’ diagnostic or therapeutic medical devices managed by central hospital departments, such as CT scanners or radiotherapy machines.

Note: the *learned intermediary doctrine* is referred to in the 2021 WHO report on *Ethics and Governance of Artificial Intelligence for Health*, under the heading “Are machine-learning algorithms products”?

<https://www.who.int/publications/i/item/9789240029200>

See also [Section 6.12](#) above, relating specifically to AI-enabled devices.

⁵ Continuous positive airway pressure. A CPAP machine is used for the treatment of sleep apnoea.

13. Programming languages and tools

13.1 Microsoft Excel™

Reference in the text: Section 3.3.3

It is now possible to write Python code directly from within Excel, which has several potential benefits for data scientists:

<https://www.kdnuggets.com/python-in-excel-this-will-change-data-science-forever>

(written 18 September 2023, accessed 22 February 2024)

Given that Microsoft's LLM can now be accessed from within Microsoft 365 apps (including Excel), this provides a Python code generating tool that can potentially be used to produce a range of AI-based applications.

<https://blogs.microsoft.com/blog/2023/03/16/introducing-microsoft-365-copilot-your-copilot-for-work/>

However, it should be noted that this Python-in-Excel facility is currently only available when using web-based Excel (i.e. Microsoft 365), not from the locally installed Microsoft Office desktop app that most clinical scientists use.

14. Standards

14.1 Harmonisation process

Reference in the text: Section 6.3.3

The EC has recently (May 2024) published a further amendment to its original (2021) standardisation request (to CEN/CENELEC) that pushes most of the adoption deadlines from May 2024 back to May 2028!

[https://ec.europa.eu/transparency/documents-register/detail?ref=C\(2024\)3371&lang=en](https://ec.europa.eu/transparency/documents-register/detail?ref=C(2024)3371&lang=en)

This has caused consternation in some quarters and a public post on LinkedIn prompted an official response from the EC:

https://www.linkedin.com/posts/christian-rosenzweig-150810134_register-of-commission-documents-activity-7209821520267788290-l-HU/

The "bottom line" is that some standards that are key to medical device software development (e.g. IEC 62304, IEC 62366-1, IEC 81001-5-1) will probably not now be harmonised until 2028, even though they must be followed as representing the current state of the art. Note that ISO 14971 and ISO 13485 are already harmonised with respect to MDR 17.

END OF TEXT

Book reference list

This is a complete set of book references, with hyperlinks where appropriate. A few links given in the book no longer work due to the website in question being replaced or removed by the host organisation. Some links given below therefore replace the corresponding URLs given in the book. The links were checked and confirmed current as of 2 February 2024.

Note: For FDA and UK Government documents, the date given is either the date originally published, or the date last reviewed and declared “still current”, whichever is the most recent.

Chapter 1

- [1] M. Jonsson, “2021 predictions for medical device product and systems development”, *Jama Software*, December 2020.
<https://www.jamasoftware.com/blog/2021-predictions-medical-device/> [Accessed 13 October 2023].
- [2] F. Macleod and S. Richardson, “Piper alpha: The disaster in detail,” 6 July 2018.
<https://www.thechemicalengineer.com/features/piper-alpha-the-disaster-in-detail/> [Accessed 10 January 2022].
- [3] M. Wienroth, P. McCormack and T. Joyce, “Precaution, governance and the failure of medical implants: the ASR(TM) hip in the UK,” *Life Sciences, Society and Policy*, vol. 10, p. 19, 2014.
- [4] V. Martindale and A. Menache, “The PIP scandal: An analysis of the process of quality control that failed to safeguard women from the health risks,” *Journal of the Royal Society of Medicine*, vol. 106, no. 5, pp. 173–177, 2013.
- [5] R. Horton, “Offline: A serious regulatory failure, with urgent implications,” *The Lancet*, vol. 379, no. 9811, p. 106, 11 January 2012.
[https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736\(12\)60032-4.pdf](https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(12)60032-4.pdf) [Accessed 20 January 2024]
- [6] M. Eikermann, C. Gludd and C. Perleth, “Commentary: Europe needs a central, transparent, and evidence-based regulation process for devices,” *British Medical Journal*, vol. 346, p. f2771, 2013.
- [7] B. Kramer, S. Xu and A. Kesselheim, “How does medical device regulation perform in the United States and the European union? A systematic review,” *PLoS Medicine*, vol. 9, no. 7, p.e1001276, 2012.
<https://core.ac.uk/download/pdf/28941081.pdf>
- [8] D. Zuckerman, P. Brown and S. Nissen, “Medical device recalls and the FDA approval process,” *Archives of Internal Medicine*, vol. 171, no. 11, pp. 1006–1011, 2011.
- [9] “Regulating medical devices in the UK,” July 2023.
<https://www.gov.uk/guidance/regulating-medical-devices-in-the-uk> [Accessed 13 October 2023].
- [10] S. Anand, “How many lines of code is Google Chrome,” 24 August 2012.
<https://www.quora.com/How-many-lines-of-code-is-Google-Chrome> [Accessed 12 October 2023].
- [11] M. Reiser, *The Oberon System User Guide and Programmer’s Manual*, New York: ACM Press, 1991.

- [12] W. Gibbs, "Software's chronic crisis," *Scientific American*, vol. 271, no. 3, pp. 86–95, 1994.
<https://www.cse.psu.edu/~gxt29/bug/localCopies/SoftwareCrisis.html>
- [13] R. Somers, "The coming software apocalypse," *The Atlantic*, 26 September 2017.
<https://www.theatlantic.com/technology/archive/2017/09/saving-the-world-from-code/540393/>
 [Accessed 21 January 2022].
- [14] A. Barr, *The problem with software: why smart engineers write bad code*, Boston: MIT Press, 2018.

Chapter 2

- [1] "The big debate: Defining medical devices," *Scope*, vol. 29, no. 3, pp. 14–17, 2000.
<https://www.ipem.ac.uk/resources/other-resources/?resourceType=2128>
- [2] MHRA, "Software flowchart: Appendix 2 - Clinical calculators," 2020.
https://assets.publishing.service.gov.uk/media/64a7d23c7a4c230013bba33e/Appendix_2_-_clinical_calculators.pdf [Accessed 12 September 2023].
- [3] FDA, "Part 11, Electronic records; electronic signatures - scope and application," September 2003.
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application> [Accessed 14 September 2023].
- [4] Johner Institute, "21 CFR Part 11: You should know these requirements," 6 June 2018.
<https://www.johner-institute.com/articles/regulatory-affairs/and-more/21-cfr-part-11/>
 [Accessed 12 September 2023].
- [5] T. Phan, "Validation of electronic spreadsheets for complying with 21 CFR Part 11", *Pharmaceutical Technology*, Vol 27, No 1, pp. 50–62, January 2003.
- [6] QIMacros, "21 CFR 11 compliance for the FDA"
<https://www.qimacros.com/support/21cfr11-compliance/> [Accessed 12 September 2023].
- [7] N. Hrgarer, "A management approach to software validation requirements," in *Central European Conference on Information and Intelligent Systems (CECIIS)*, Varazdin, Croatia, 2008.
- [8] Perficient, "The ultimate guide to CFR part 11".
<https://www.perficient.com/-/media/files/guide-pdf-links/the-ultimate-guide-to-21-cfr-part-11.pdf>
 [Accessed 12 September 2023].
- [9] CSV Compliance, "Spreadsheet validation of 21 CFR Part 11
<https://www.spreadsheetvalidation.com/> [Accessed 12 September 2023].
- [10] Greenlight Guru, "CSA vs. CSV: Modern validation for modern MedTech," 7 July 2023.
<https://www.greenlight.guru/blog/computer-systems-validation-vs-computer-software-assurance-medtech> [Accessed 12 September 2023].
- [11] European Commission, "Good manufacturing practice: Annex 11: Computerised systems," 30 June 2011.
https://health.ec.europa.eu/system/files/2016-11/annex11_01-2011_en_0.pdf
 [Accessed 12 September 2023].

- [12] Florence Healthcare, “EU Annex 11: How to stay compliant”.
<https://florencehc.com/blog-post/eu-annex-11-how-to-stay-compliant/> [Accessed 12 September 2023].
- [13] FDA, “Is a new 510(k) required for a modification to the device?” 31 October 2017.
<https://www.fda.gov/medical-devices/premarket-notification-510k/new-510k-required-modification-device> [Accessed 12 September 2023].
- [14] FDA, “Deciding when to submit a 510(k) for a software change to an existing device”, 25 October 2017.
<https://www.fda.gov/media/99785/download> [Accessed 12 September 2023].
- [15] FDA, “Artificial intelligence and machine learning in software as a medical device”, 22 September 2021.
<https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-software-medical-device> [Accessed 12 September 2023].
- [16] University of Sheffield, UK, “Research software engineering,”
<https://rse.shef.ac.uk/> [Accessed 13 September 2023].
- [17] Mitratech, “Configuration vs customization – What’s the difference and why does it matter”? 20 June 2017.
https://mitratech.com/en_gb/resource-hub/blog/configuration-vs-customization-whats-difference-matter/ [Accessed 12 September 2023].
- [18] Distillery, “In-house or outsourcing software development: A strategic guide,” 29 October 2019. <https://distillery.com/blog/in-house-or-outsourced-which-software-development-path-is-right-for-you/> [Accessed 12 September 2023].
- [19] J. McCarthy, “MDR: The health institution exemption and MHRA draft guidelines”, *Scope*, vol. 27, no. 3, pp. 24–27, 2018.
<https://www.ipem.ac.uk/resources/other-resources/?resourceType=2128>
[Accessed 14 September 2023].
- [20] S. Morrin, “Did you need a degree to land your job?”, LinkedIn, July 2023.
https://www.linkedin.com/posts/linkedin-news-uk_did-you-need-a-degree-to-land-your-job-activity-7097618976519704576-t-rV/ [Accessed 12 September 2023].
- [21] T. Brown, “Ultimate guide to training management for medical device companies”, Greenlight Guru, 7 February 2021.
<https://www.greenlight.guru/blog/training-management-medical-device>
[Accessed 12 September 2023].
- [22] IPeM, “Becoming a clinical scientist,”
<https://www.ipem.ac.uk/your-career/getting-started-on-a-career-in-mpce/becoming-a-clinical-scientist/> [Accessed 10 September 2023].
- [23] National School of Healthcare Science, “Scientists training programme,” NHS England.
<https://nshcs.hee.nhs.uk/programmes/stp/> [Accessed 10 September 2023].
- [24] National School of Healthcare Science, “Clinical scientific computing curriculum”, NHS England.
<https://curriculumlibrary.nshcs.org.uk/stp/specialty/SBI1-2-22/>
[Accessed 10 September 2023].

- [25] National School of Healthcare Science, “Software module S-BG-S2 curriculum”, NHS England. <https://curriculumlibrary.nshcs.org.uk/stp/module/S-BG-S2/> [Accessed 10 September 2023].
- [26] Royal Surrey County Hospital, “STP computing in healthcare course,” <https://medphys.royalsurrey.nhs.uk/courses/> [Accessed 10 September 2023].
- [27] University of Nottingham, “Software engineer online bootcamp”. <https://exchange.nottingham.ac.uk/blog/university-of-nottingham-online-and-hyperiondev-offer-coding-bootcamps/> [Accessed 10 October 2023].
- [28] Software Engineering Institute, “Courses,” Carnegie Mellon University <https://www.sei.cmu.edu/education-outreach/courses/> [Accessed 10 October 2023].
- [29] A. Del Guerra and M. Bardies, “Curriculum for education and training of medical physicists in nuclear medicine: Recommendations from the EANM Physics Committee, the EANM Dosimetry Committee and EFOMP,” *European Journal of Medical Physics*, vol. 29, no. 2, pp. 139–162, 2013.
- [30] L. Fraser, N. Parkar, K. Adamson et al, “Policy statement: Medical physics Expert support for nuclear medicine,” IPEM, BIR, 2022. <https://www.ipem.ac.uk/media/2wgox5uy/mpesup-2.pdf> [Accessed 10 September 2023].
- [31] European Federation for Organisations for Medical Physics (EFOMP), “Core curriculum for medical physics experts in Radiotherapy (Revised 3rd Edition)”. https://www.efomp.org/uploads/595e3c8a-52d9-440f-b50b-183c3a00cb00/Radiotherapy_cc_2022.pdf [Accessed 10 September 2023].
- [32] J. Price, M. Barnfield and J. Cullis, “Variation in software platforms including the use of in-house analysis in nuclear medicine – results from a UK survey (abstract),” *Nuclear Medicine Communications*, vol. 42, pp. 1162–1185, 2021.
- [33] J. Helmenkamp, R. Bujila and G. Poludniowski, *Diagnostic Radiology Physics with MATLAB*, London: CRC Press, 2021.
- [34] Institute of Physics and Engineering in Medicine, “Clinical and scientific computing special interest group”. <https://www.ipem.ac.uk/about/special-interest-groups/clinical-and-scientific-computing-group/> [Accessed 10 September 2023].
- [35] L. Tasker and R. Nix, “Medical device regulatory compliance: Swansea’s experience,” *Scope*, vol. 33, no. 2, pp. 32–35, 2023. <https://www.ipem.ac.uk/resources/other-resources/?resourceType=2128> [Accessed 12 September 2023].
- [36] G. Wilson, D. Aruliah and C. Brown, “Best Practices for Scientific Computing,” *PLoS Biology*, vol. 12, no. 1, 2014: e1001745. <https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1001745> [Accessed 12 September 2023].
- [37] C. Laporte, R. O’Connor and L. García Paucar, “The implementation of ISO/IEC 29110 software engineering standards and guides in very small entities,” in *Evaluation of Novel Approaches to Software Engineering*, L. Maciaszek, Ed., Springer, Cham, 2015, pp. 162–179 https://link.springer.com/chapter/10.1007/978-3-319-30243-0_9 [Accessed 25 November 2023].
- [38] W. Tindale, P. Thornley and T. Nunan, “A survey of the role of the UK physicist in nuclear medicine: A report of a joint working group of the BIR, BNMS and IPEM”,

Nuclear Medicine Communications, vol. 24, no. 1, pp. 91–100, 2003.

[39] IPEM, “Why and how to regulate software in the healthcare setting - Part 1,” 2022.
<https://www.ipem.ac.uk/resources/other-resources/webinars/why-and-how-to-regulate-software-in-the-healthcare-setting-part-1/>. [Accessed 10 September 2023].

Note: This reference is no longer available: See Clinical Safety in Health IT Systems. 24 April 2023.
<https://www.ipem.ac.uk/resources/other-resources/webinars/clinical-safety-in-health-it-systems/>

[40] E. Ng’An’ga and I. Tonui, “A survey on software sizing for project estimation”, *International Journal of Software Engineering*, vol. 5, no. 4, pp. 56–58, 2015.

[41] R. Grade and D. Caswell, “The need for tools,” in *Software metrics: Establishing a Company-Wide Program*, New Jersey, Prentice-Hall, 1987, pp. 112–114.

[42] Wikipedia, “Capability maturity model.
https://en.wikipedia.org/wiki/Capability_Maturity_Model [Accessed 10 September 2023].

[43] IPEM, “Best-practice guidance for the in-house manufacture of medical devices and non-medical devices, including software in both cases, for use within the same health institution”, 25 July 2022.
<https://www.ipem.ac.uk/media/vp0ewy01/ipembe-1.pdf> [Accessed 10 September 2023].

[44] H. Gislasen, “Excel vs. Google Sheets usage - nature and numbers,” GRID, 28 August 2018.
<https://medium.grid.is/excel-vs-google-sheets-usage-nature-and-numbers-9dfa5d1cadbd>
[Accessed 13 September 2023].

Chapter 3

[1] Jama software, “The rapid rise of digital health technology - Challenges and keys to success”, 22 November 2021.
<https://www.jamasoftware.com/blog/key-takeaways-the-rapid-rise-of-digital-health-technology-challenges-and-keys-to-success/>
[Accessed 10 September 2023].

[2] MDCG, “MDCG 2019-11. Guidance on qualification and classification of software in regulation (EU) 2017/745 – MDR and regulation (EU) 2017/746 – IVDR,” October 2019.
<https://ec.europa.eu/docsroom/documents/37581>
[Accessed 10 September 2023].

[3] FDA, “Software as a Medical Device (SaMD)”, 4 December 2018.
<https://www.fda.gov/medical-devices/digital-health-center-excellence/software-medical-device-samd>
[Accessed 8 September 2023].

[4] IMDRF, ““Software as a Medical Device: Possible framework for risk categorization and corresponding considerations”, 18 September 2014.
<https://www.imdrf.org/sites/default/files/docs/imdrf/final/technical/imdrf-tech-140918-samd-framework-risk-categorization-141013.pdf> [Accessed 10 September 2023].

[5] Ropes and Gray, “FDA overhauls its draft guidance on Clinical Decision Support (“CDS”) software”, 7 October 2019.

<https://www.ropesgray.com/en/insights/alerts/2019/10/fda-overhauls-its-draft-guidance-on-clinical-decision-support-cds-software> [Accessed 9 September 2023].

[6] S. Agarwal, A. LeFevre and L. Jaime, “Guidelines for reporting of health interventions using mobile phones: Mobile health (mHealth) evidence reporting and assessment (mERA) checklist,” *British Medical Journal*, vol. 352, p. 1174, 2016.

[7] J. Kwan, L. Lo and J. Ferguson, “Computerised clinical decision support systems and absolute improvements in care: meta-analysis of controlled clinical trials,” *British Medical Journal*, vol. 320, p. 3216, 2020.

[8] Agency for Healthcare Research and Quality, “Clinical decision support,” June 2019. <https://www.ahrq.gov/cpi/about/otherwebsites/clinical-decision-support/index.html> [Accessed 8 September 2023].

[9] Centers for Disease Control and Prevention, “What is clinical decision support?”, 22 August 2022. <https://www.cdc.gov/opioids/healthcare-admins/ehr/clinical-decision-support.html> [Accessed 8 September 2023].

[10] The Office of the National Coordinator for Health Information Technology (ONC), “Clinical decision support”. <https://www.healthit.gov/topic/safety/clinical-decision-support> [Accessed 8 September 2023].

[11] US National Academy of Medicine, “Clinical decision support”, 2017. https://www.healthit.gov/sites/default/files/page/2018-04/Optimizing_Strategies_508.pdf [Accessed 8 September 2023].

[12] MHRA, “Guidance: Medical device stand-alone software including apps (including IVDMDs)”, 1 July 2023. <https://www.gov.uk/government/publications/medical-devices-software-applications-apps> [Accessed 8 September 2023].

[13] Wikipedia, “Spreadsheet,” <https://en.wikipedia.org/wiki/Spreadsheet>. <https://en.wikipedia.org/wiki/Spreadsheet> [Accessed 8 September 2023].

[14] Visual Studio Magazine, “Microsoft’s new programming language for Excel now Turing complete”. <https://visualstudiomagazine.com/articles/2021/01/27/excel-lambda.aspx> [Accessed 8 September 2023].

[15] BSI/AAMI, “Machine learning AI in medical devices: Adapting regulatory frameworks and standards to ensure safety and performance”. 2020. <https://www.ethos.co.im/wp-content/uploads/2020/11/MACHINE-LEARNING-AI-IN-MEDICAL-DEVICES-ADAPTING-REGULATORY-FRAMEWORKS-AND-STANDARDS-TO-ENSURE-SAFETY-AND-PERFORMANCE-2020-AAMI-and-BSI.pdf> [Accessed 10 September 2023].

[16] J. Diao, K. Venkatesh, M. Raza and J. Kvedar, “Multinational landscape of health app policy: Toward regulatory consensus on digital health,” *NPJ Digital Medicine*, vol. 5, p. 61, 2022.

[17] FDA, “Device software functions including mobile medical applications”, 29 September 2022. <https://www.fda.gov/medical-devices/digital-health-center-excellence/device-software-functions-including-mobile-medical-applications> [Accessed 10 September 2023].

[18] D. Neal, T. Engelsma and J. Tan, “Limitations of the new ISO standard for health and wellness apps,” *The Lancet Digital Health*, vol. 4, no. 2, pp. E80–E82, 2022.

[19] ORCHA, “Check your app against NHS DTAC”, 17 February 2021.
<https://orchahealth.com/check-your-apps-against-dtac/> [Accessed 11 September 2023].

[20] OrielStat, “Medical device production, QMS and NPS software risk assessment, validation, and protocols”, 25 May 2023.
<https://www.orielstat.com/blog/nps-non-product-software-risk-assessment/>
[Accessed 10 September 2023].

Chapter 4

[1] F. Redmill, “Software in safety critical applications - A review of current issues,” in *Safety critical systems: Current issues, techniques and standards*, London, Chapman and Hall, 1993, pp. 3–15.

[2] C. Peace, “The risk matrix: Uncertain results?”, *Policy and Practice in Health and Safety*, vol. 15, no. 2, pp. 131–144, 2017.
https://www.researchgate.net/publication/318382514_The_risk_matrix_Uncertain_results
[Accessed 26 January 2024].

[3] OrielStat, “How medical device risk management and ISO 14971:2019 work”, 21 March 2023.
<https://www.orielstat.com/blog/iso-14971-risk-management-basics/> [Accessed 13 September 2023].

[4] Greenlight Guru, “ISO 14971 risk management for medical devices: The definitive guide,” 11 May 2023. <https://www.greenlight.guru/blog/iso-14971-risk-management>
[Accessed 11 September 2023].

[5] Notified Bodies Recommendation Group, “Consensus paper for the interpretation and application of Annexes Z in EN ISO 14971:2012,” 13 October 2014.
https://www.team-nb.org/wp-content/uploads/2017/08/NBRG_WG-RM_Interim_NBmed_Consensus_Version_140812_1_1.pdf [Accessed 8 September 2023].

[6] FDA, “Factors to consider regarding benefit-risk in medical device product availability, compliance, and enforcement decisions”, 27 December 2016.
<https://www.fda.gov/media/98657/download> (*this can replace the complex URL given in the book*)
[Accessed 11 September 2023].

[7] L. Cox, “What’s wrong with risk matrices?”, *Risk Analysis*, vol. 28, no. 2, pp. 497–512, 2008.
<https://pubmed.ncbi.nlm.nih.gov/18419665/> (abstract). [Accessed 26 January 2024].

[8] Engineering Safety Consultants, “Quantitative Risk Assessment (QRA)”.
<https://esc.uk.net/quantitative-risk-assessment/> [Accessed 14 September 2023].

[9] A. Sidorenko, “An alternative to risk matrices”, *Corporate Compliance Insights*, 1 July 2019.
<https://www.corporatecomplianceinsights.com/alternative-risk-matrices/>
[Accessed 12 September 2023].

Chapter 5

- [1] T. Rish, "Ultimate list of ISO standards for medical devices," Greenlight Guru, 14 July 2023. <https://www.greenlight.guru/blog/iso-standards> [Accessed 11 September 2023].
- [2] J. Speer, "Ultimate guide to ISO 13485 for medical device QMS," Greenlight Guru, 16 February 2023. <https://www.greenlight.guru/blog/iso-13485-qms-medical-device> [Accessed 12 September 2023].
- [3] E. Nichols, "Best QMS software: Ultimate guide to comparing quality management system solutions", Greenlight Guru, 17 March 2023. <https://www.greenlight.guru/blog/best-qms-software-quality-management> [Accessed 12 September 2023].
- [4] OrielStat, "Medical device quality management system (QMS): What it is, where it's required, and key regulations to know", 13 June 2018. <https://www.orielstat.com/blog/medical-device-qms-overview/> [Accessed 15 September 2023].
- [5] D. Lundy, "RIM vs eQMS software for medical device manufacturers," Rimsys, 20 January 2023. <https://www.rimsys.io/blog/rim-vs-eqms-software-for-medical-device-manufacturers> [Accessed 14 September 2023].
- [6] Advisera, "Project plan for ISO 13485 implementation". <https://info.advisera.com/13485academy/free-download/project-plan-for-iso-13485-implementation-presentation> (PowerPoint presentation, also available as Word document): <https://info.advisera.com/13485academy/free-download/project-plan-for-iso-134852016-implementation> [Accessed 11 September 2023].
- [7] Advisera, "ISO 13485:2016 gap analysis tool". <https://advisera.com/13485academy/iso-13485-gap-analysis-tool/> [Accessed 10 September 2023].
- [8] Advisera, "Project proposal for ISO 13485:2016 implementation," <https://info.advisera.com/13485academy/free-download/project-proposal-for-iso-13485-implementation-word> [Accessed 11 September 2023].
- [9] Advisera, "ISO 13485 and MDR integrated documentation toolkit". <https://advisera.com/13485academy/iso-13485-eu-mdr-documentation-toolkit/> [Accessed 11 September 2023].
- [10] E. Nichols, "The ultimate internal audit checklist every medical device company needs," Greenlight Guru, 25 October 2022. <https://www.greenlight.guru/blog/internal-audit-checklist-medical-device> [Accessed 12 September 2023].
- [11] B. Wichman, G. Parkin and R. Barker, "NPL software support for Metrology: Best Practice Guide No 1 - Validation of software in measurement systems," Software Support for Metrology 2007. https://eprintspublications.npl.co.uk/3922/1/DEM_ES14.pdf [Accessed 11 September 2023].
- [12] UKAS, "Medical physics and clinical engineering accreditation". <https://www.ukas.com/accreditation/standards/mpace/> [Accessed 11 September 2023].
- [13] UKAS, "Accreditation vs certification: What's the difference?". <https://www.ukas.com/accreditation/about/accreditation-vs-certification/> [Accessed 19 September 2023].

- [14] IPEM, “Guidance for health institutions on in-house manufacture and use, including software (2nd Edition)”, 25 July 2022.
<https://www.ipem.ac.uk/resources/other-resources/statements-and-notice/guidance-for-in-house-manufacture-of-medical-devices-and-non-medical-devices-including-software-2nd-ed/>
[Accessed 19 September 2023].
- [15] UKAS, “Medical physics & clinical engineering accreditation: FAQs”.
<https://www.ukas.com/wp-content/uploads/2022/02/MPACE-FAQ-Jan-2022.pdf>
[Accessed 19 September 2023].
- [16] R. Van Vroonhoven, “Risk management for medical devices and the new BS EN ISO 14971”, BSI, July 2022.
https://www.bsigroup.com/globalassets/localfiles/en-us/images/wp_risk_management_web.pdf
[Accessed 11 September 2023].
- [17] FDA, “Recognized consensus standards: Medical devices”, 14 January 2019.
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfstandards/detail.cfm?standard_identification_no=38829 [Accessed 11 September 2023].
- [18] FDA, “General principles of software validation”, January 2022.
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-principles-software-validation> [Accessed 11 September 2023].
- [19] Johner Institute, “IEC 81001-5-1: The standard for secure health software”.
<https://www.johner-institute.com/articles/software-iec-62304/and-more/iec-81001-5-1-the-standard-for-secure-health-software/> [Accessed 11 September 2023].
- [20] Medical Device HQ, “The IEC 62304 standard and configuration management”, 25 June 2020.
<https://medicaldevicehq.com/articles/the-iec-62304-standard-and-configuration-management/>
[Accessed 14 September 2023].
- [21] A. Marinelli and H. Mann, “Agile software development in bio/pharma & medical devices, Part 3”, Outsourced Pharma, 25 July 2023
<https://www.outsourcedpharma.com/doc/agile-software-development-in-bio-pharma-medical-devices-part-0003> (URL given in the book). [Accessed 11 September 2023].
- [22] R. Sheldon, “What is Git?”, Tech Target, February 2023.
<https://www.techtarget.com/searchitoperations/definition/Git> [Accessed 19 September 2023].
- [23] Y. Wang and P. Khopkar, “Good programming practices” in *Diagnostic Radiology Physics with MATLAB®*, J. Helmenkamp, Ed., London: CRC Press, 2021, pp. 79–87.
- [24] i3cglobal, “IEC 62304/ISO 62304”.
<https://www.i3cglobal.com/iso-iec-62304-procedures/> [Accessed 11 September 2023].
- [25] M. Dahlke and R. Ginsberg, “Safety risk management of software”, *RF Quarterly*, vol. 2, no. 1, pp. 35–54, 1 April 2022.
- [26] FDA, “Off-the-shelf software use in medical devices”, August 2023.
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/shelf-software-use-medical-devices> [Accessed 11 September 2023].
- [27] MD101, “Got SOUP? - Part 1 - Because every good software starts with SOUP”, 17 May 2013.

<https://blog.cm-dm.com/post/2013/05/10/Got-SOUP-Part-1-Because-every-good-software-starts-with-SOUP> [Accessed 11 September 2023].

[28] P. S. Cosgriff and J. Atting, “Regulatory considerations when deploying your software in a clinical environment”, in *Diagnostic Radiology Physics with MATLAB*, CRC Press, London, 2021, pp. 105–126.

[29] Johner Institute, “SOUP – Software of Unknown Provenance”, 10 December 2015. <https://www.johner-institute.com/articles/software-iec-62304/soup-and-ots/> [Accessed 18 September 2023].

[30] M. Steck, “IEC 62304 software development”, Integrated Scientific Services, 28 April 2020. https://www.aligned.ch/images/BlogPictures/Sharpen_2020/IEC62304.pdf [Accessed 12 September 2023].

[31] P. Massey, “Making AAMI TIR45 work for your software teams”, Bluefruit Software, 25 November 2020. <https://www.linkedin.com/pulse/making-aami-tir45-work-your-software-teams-paul-massey/> [Accessed 11 September 2023].

[32] AAMI, “AAMI TIR45:2023”, 2023. <https://webstore.ansi.org/standards/aami/aamitir452023> [Accessed 19 September 2023].

[33] M. McHugh, F. McCaffery and V. Casey, “Adopting agile practices when developing software for use in the medical domain,” *Journal of Software Evolution and Process*, vol. 26, no. 5, pp. 504–512, 2014.

[34] M. Kostić, “Challenges of agile practices implementation in the medical device software development methodologies”, *European Project Management Journal*, vol. 7, no. 2, pp. 36–44, 2017.

[35] FDA, “Recognized consensus standards: Medical devices”, 11 September 2023. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfstandards/detail.cfm?standard_identification_no=30575 [Accessed 20 September 2023].

[36] FDA, “Appropriate use of voluntary consensus standards in submissions for medical devices”, 14 September 2018. <https://www.fda.gov/media/71983/download> [Accessed 20 September 2023].

[37] COCIR, “Artificial intelligence in EU medical device legislation”, May 2021. https://www.cocir.org/fileadmin/Publications_2021/COCIR_Analysis_on_AI_in_medical_Device_Legislation_-_May_2021.pdf [Accessed 20 September 2023].

[38] MD101, “IEC 82304-1 - Consequences on agile software development processes”, 8 April 2016. <https://blog.cm-dm.com/post/2016/04/08/IEC-82304-1-Consequences-on-agile-software-development-processes> [Accessed 20 September 2023].

[39] IEEE Computer Society, “Software Engineering Body of Knowledge (SWEBOK)”. <https://www.computer.org/education/bodies-of-knowledge/software-engineering> [Accessed 20 September 2023].

[40] IEEE, “Software Engineering Body of Knowledge (SWEBOK)”. <https://www.ieee.org/about/ieee-india/ieee-computer-society-india/swebok.html> [Accessed 20 September 2023].

- [41] Stack Exchange, “What needs to change for software engineering to become a formal profession”, 2015.
<https://softwareengineering.stackexchange.com/questions/196829/what-needs-to-change-for-software-engineering-to-become-a-formal-profession> [Accessed 20 September 2023].
- [42] S. Kumar Pal, “Coding standards and guidelines”, Geeks for geeks, 28 June 2022.
<https://www.geeksforgeeks.org/coding-standards-and-guidelines/>
[Accessed 20 September 2023].
- [43] S. Bose, “Coding standards and best practices to follow”, Browser Stack, 20 April 2023.
<https://www.browserstack.com/guide/coding-standards-best-practices>
[Accessed 20 September 2023].
- [44] G. Wilson, D. Aruliah and A. Brown, “Best practices for scientific computing”, *PloS Biology*, vol. 12, no. 1, p. e1001745, 2014.
- [45] R. Martin, *Clean Code: A Handbook of Agile Software Craftsmanship*, Boston, MA: Prentice Hall, 2008.
- [46] W. Lukaszuk, “Clean code”, GitHub, 2022
<https://gist.github.com/wojteklu/73c6914cc446146b8b533c0988cf8d29>
[Accessed 20 September 2023].
- [47] R. Zain, “The clean code manifesto”, 11 April 2022.
<https://medium.com/@RadhiansyaZ/the-clean-code-manifesto-4505605df83b>
[Accessed 20 September 2023].
- [48] GNU, “GNU coding standards”.
<https://www.gnu.org/prep/standards/standards.html#Formatting> [Accessed 20 September 2023].
- [49] MISRA, “MISRA main site”.
<https://misra.org.uk> [Accessed 20 September 2023].
- [50] MathWorks, “What is MISRA C?”.
<https://uk.mathworks.com/discovery/misra-c.html> [Accessed 20 September 2023].
- [51] DevIQ, “Guard clause”.
<https://deviq.com/design-patterns/guard-clause> [Accessed 20 September 2023].
- [52] O. Yenigun, “Defensive programming in Python”, 27 September 2022.
<https://python.plainenglish.io/defensive-programming-in-python-af0266e65dfd>
[Accessed 20 September 2023].
- [53] European Spreadsheet Risks Interests Group, “Horror stories”.
<https://eusprig.org/research-info/horror-stories/> [Accessed 20 September 2023].
- [54] European Spreadsheet Risk Interest Group, “Research and best practice”.
<https://eusprig.org/research-info/research-and-best-practice> [Accessed 20 September 2023].
- [55] B. Weber, “Strategies for addressing spreadsheet compliance challenges”, in *Proc. European Spreadsheet Risks Int. Grp.*, 2006.
- [56] R. Barker, M. Harris and G. Parkin, “NPL Software support for Metrology best practice guide #7 - Development and testing of spreadsheet applications”, 2006.

<https://eprintspublications.npl.co.uk/3878/> [Accessed 20 September 2023].

[57] PCW, “Global financial modelling guidelines (v3.0)”, January 2020.
<https://www.pwc.com.au/deals/assets/pwc-global-financial-modeling-guidelines-booklet-live.pdf>
[Accessed 20 September 2023].

[58] B. Dickson, “Microsoft and OpenAI get ahead in the LLM competition”, TechTalks, 28 March 2023.
<https://bdtechtalks.com/2023/03/28/microsoft-openai-llm-competition/>
[Accessed 20 September 2023].

[59] European Commission, “Code of conduct on privacy for mHealth apps has been finalised”, 07 June 2016.
<https://digital-strategy.ec.europa.eu/en/library/code-conduct-privacy-mhealth-apps-has-been-finalised>
[Accessed 20 September 2023].

[60] BSI, “PAS 277:2015 - Health and wellness apps. Quality criteria across the life cycle: Code of practice”, 30 April 2015.
<https://knowledge.bsigroup.com/products/health-and-wellness-apps-quality-criteria-across-the-life-cycle-code-of-practice?version=standard> [Accessed 20 September 2023].

[61] NHS England, “Digital and data-driven health and care technology - A guide to good practice for digital and data-driven health technologies”, 19 January 2021.
<https://www.gov.uk/government/publications/code-of-conduct-for-data-driven-health-and-care-technology> [Accessed 20 September 2023].

[62] NHS England, “Digital Technology Assessment Criteria”.
<https://transform.england.nhs.uk/key-tools-and-info/digital-technology-assessment-criteria-dtac/>
[Accessed 20 September 2023].

[63] A. Downey, “NHSX launches assessment criteria for digital health tools”, Digital Health, 26 October 2020.
<https://www.digitalhealth.net/2020/10/nhsx-launches-assessment-criteria-for-digital-health-tools/>
[Accessed 20 September 2023].

[64] FDA, “Policy for device software functions and mobile medical applications”, September 2022.
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-device-software-functions-and-mobile-medical-applications> [Accessed 20 September 2023].

[65] A. Marinelli and H. Mann, “Agile software development in bio/pharma & medical devices, Part 1”, Outsourced Pharma, 27 July 2023.
<https://www.outsourcedpharma.com/doc/agile-software-development-in-bio-pharma-medical-devices-part-0001> [Accessed 20 December 2023].

Appendix 1.4.1

Good Practices for Health Applications of Machine Learning; Considerations for Manufacturers and Regulators. International Telecommunication Union Focus Group, September 2022)
https://www.itu.int/dms_pub/itu-t/opb/fg/T-FG-AI4H-2022-2-PDF-E.pdf
(This replaces the URL given in the text)

Chapter 6

- [1] C. Sorenson and M. Drummond, “Improving medical device regulation: The United States and Europe in perspective”, *Milbank Quarterly*, vol. 92, no. 1, pp. 114–150, 2014.
- [2] R. A. Miller and R. M. Gardner, “Recommendations for responsible monitoring and regulation of clinical software systems”, *Journal of the American Medical Informatics Association*, vol. 4, no. 6, pp. 442–457, 1997.
- [3] UK House of Commons, “Regulation of medical implants in the UK”, 17 October 2012.
<https://publications.parliament.uk/pa/cm201213/cmselect/cmsctech/163/163.pdf>
[Accessed 20 September 2023].
- [4] P. Baird and K. Cobbaert, “Software as a medical device: A comparison of the EU’s approach with the US’s approach”, BSI, 2020.
<https://www.bsigroup.com/globalassets/localfiles/en-th/Medical%20devices/whitepapers/wp-software-th.pdf> [Accessed 20 September 2023].
- [5] European Commission, “The ‘Blue Guide’ on the implementation of EU product rules 2022”, 2022.
https://eur-lex.europa.eu/legal-content/EN/TXT/?toc=OJ%3AC%3A2022%3A247%3ATOC&uri=uriserv%3AOJ.C_.2022.247.01.0001.01.ENG [Accessed 20 September 2023].
- [6] European Commission, “Flowchart to assist in deciding whether or not a device is covered by the extended MDR transitional period”, 23 August 2023.
https://health.ec.europa.eu/latest-updates/flowchart-assist-deciding-whether-or-not-device-covered-extended-mdr-transitional-period-2023-08-23_en [Accessed 20 September 2023].
- [7] Medical Device Regulation, “Harmonised standards list”, 2023.
<https://www.medical-device-regulation.eu/mdr-resource-harmonized-standards-lis/>
[Accessed 20 September 2023].
- [8] European Commission, “C(2021)2406 – Standardisation request M/575”, 14 April 2021.
https://ec.europa.eu/growth/tools-databases/enorm/mandate/575_en [Accessed 20 September 2023].
- [9] MDCG, “MDCG 2019-11: Guidance on qualification and classification of software in regulation (EU) 2017/745 – MDR and Regulation (EU) 2017/746 – IVDR”, October 2019.
https://health.ec.europa.eu/system/files/2020-09/md_mdcg_2019_11_guidance_qualification_classification_software_en_0.pdf
[Accessed 20 September 2023].
- [10] MDCG, “MDCG 2020-6: Clinical evidence needed for medical devices previously CE marked under Directives 93/42/EEC or 90/385/EEC”, April 2020.
https://health.ec.europa.eu/system/files/2020-09/md_mdcg_2020_6_guidance_sufficient_clinical_evidence_en_0.pdf
[Accessed 20 September 2023].
- [11] European Commission, “Manual on borderline and classification in the community regulatory framework for medical devices”, May 2019.
https://health.ec.europa.eu/system/files/2020-08/md_borderline_manual_05_2019_en_0.pdf
[Accessed 21 September 2023].
- [12] Apple Inc., “Apple watch Series 9”, 2023.
<https://www.apple.com/uk/apple-watch-series-9> [Accessed 21 September 2023].
- [13] Australian Therapeutic Goods Administration, “Exemption for certain clinical decision support software”, August 2022.

<https://www.tga.gov.au/sites/default/files/2022-08/exemption-for-certain-clinical-decision-support-software.pdf> [Accessed 21 September 2023].

[14] Medicines & Healthcare Products Agency, “Flowchart CIs - Studies under UKMDR2002 v1”, 29 April 2022.

[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1072413/flowchart_CIs - Studies under UKMDR2002 v1 A4.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1072413/flowchart_CIs_-_Studies_under_UKMDR2002_v1_A4.pdf)

[Accessed 21 September 2023].

[15] European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry, “COCIR analysis on AI in medical device legislation - May 2021”, 05 May 2021.

[https://www.cocir.org/fileadmin/Publications_2021/COCIR_Analysis_on_AI_in_medical_Device_Legislation - May 2021.pdf](https://www.cocir.org/fileadmin/Publications_2021/COCIR_Analysis_on_AI_in_medical_Device_Legislation_-_May_2021.pdf) [Accessed 21 September 2023].

[16] MDCG, “MDCG 2021-24: Guidance on classification of medical devices”, October 2021.

https://health.ec.europa.eu/system/files/2021-10/mdcg_2021-24_en_0.pdf

[Accessed 21 September 2023].

[17] C. Johner, “MDR Rule 11: The classification nightmare”, Johner Institute, 22 July 2017.

<https://www.johner-institute.com/articles/regulatory-affairs/and-more/mdr-rule-11-software/>

[Accessed 21 September 2023].

[18] FME, “MDR guide for medical device software”, 09 September 2021.

<https://www.fme.nl/system/files/publicaties/2021-09/MDR%20Guide.pdf>

[Accessed 21 September 2023].

[19] C. Johner, “Klasse-I-Software (Class I software)”, Johner Institute, 20 December 2022.

<https://www.johner-institut.de/blog/iec-62304-medizinische-software/klasse-i-software/>

[Accessed 21 September 2023].

[20] O. Eidel, “How to classify software as a medical device under the MDR? (MDCG 2021–24)”, Open Regulatory, 24 May 2023.

<https://openregulatory.com/mdcg-2021-24-examples-for-software-classification-of-software-as-a-medical-device-samd/> [Accessed 21 September 2023].

[21] Mindtec Store, “BILD test winner 2021: Mobile ECG devices”, 06 July 2021.

<https://www.mindtecstore.com/BILD-test-winner-2021-of-the-mobile-ECG-devices-The-KardiaMobile-6L> [Accessed 21 September 2023].

[22] M. Kruszynska, “What is the EU MDR”, 14 October 2021.

<https://spyro-soft.com/blog/healthcare/eu-mdr-regulation> [Accessed 27 January 2024]

This replaces the reference given in the book.

[23] MHRA, “Medical devices: Software applications (apps)”, 1 July 2023.

<https://www.gov.uk/government/publications/medical-devices-software-applications-apps>

[Accessed 22 September 2023].

[24] European Commission, “Manual on borderline and classification in the community regulatory framework for medical devices (September 2022)”, 07 September 2022.

https://health.ec.europa.eu/latest-updates/manual-borderline-and-classification-community-regulatory-framework-medical-devices-september-2022-2022-09-07_en

[Accessed 21 September 2023].

[25] Institute of Physics and Engineering in Medicine, “Guidance for health institutions on in-house manufacture and use, including software (2nd Ed.)”, 25 July 2022.

<https://www.ipem.ac.uk/media/vp0ewy01/ipembe-1.pdf> (this replaces URL given in the book)
[Accessed 21 January 2024].

[26] Greenlight Guru, “SaMD gap assessment tool - Free download”, 2022.
<https://www.greenlight.guru/downloads/samd-gap-assessment-tool>
[Accessed 21 September 2023].

[27] A. Murray, “Nuclear medicine software: Nothing is perfect”, *Nuclear Medicine Communications*, vol. 35, no. 11, pp. 1093–1095, 2014.

[28] A. W. Murray, R. S. Lawson and S. C. Cade, “UK audit of glomerular filtration rate measurement from plasma sampling in 2013”, *Nuclear Medicine Communications*, vol. 35, no. 11, pp. 1096–1106, 2014.

[29] Medicines and Healthcare Products Regulatory Agency, “Guidance for manufacturers on reporting adverse incidents involving software as a medical device under the vigilance system”, May 2023.
<https://www.gov.uk/government/publications/reporting-adverse-incidents-involving-software-as-a-medical-device-under-the-vigilance-system>
[Accessed 20 September 2023].

[30] D. Reinsch, “Regulatorische Anforderungen an Medizinprodukte mit Machine Learning (Regulatory requirements for medical devices with machine learning)”, Johner Institute, 26 January 2024.
<https://www.johner-institut.de/blog/regulatory-affairs/regulatorische-anforderungen-an-medizinprodukte-mit-machine-learning/> [accessed 27 January 2024].

[31] British Standards Institute, “Machine learning AI in medical devices | BSI America”, 2020.
<https://www.bsigroup.com/en-US/medical-devices/resources/Whitepapers-and-articles/machine-learning-ai-in-medical-devices/> [Accessed 21 September 2023].

[32] European Commission, “Guidance on significant changes regarding the transitional provision under Article 120 of the MDR with regard to devices covered by certificates according to MDD or AIMDD”, 15 March 2020.
<https://ec.europa.eu/docsroom/documents/40301>
[Accessed 21 September 2023].

[33] Johner Institute, “Guideline for AI for medical products”, 21 December 2021.
https://github.com/johner-institut/ai-guideline/blob/master/Guideline-AI-Medical-Devices_EN.md
[Accessed 21 September 2023].

[34] B. North, “The growing role of human factors and usability engineering for medical devices”, 09 February 2018.
<https://www.bsigroup.com/LocalFiles/de-de/Medizinprodukte/Growing-role-of-human-factors.pdf>
[accessed 26 January 2024]

[35] European Commission, “MDCG 2019-16 - Guidance on cybersecurity for medical devices”, 06 January 2020.
<https://ec.europa.eu/docsroom/documents/41863> [Accessed 21 September 2023].

[36] European Commission, “C(2021)2406 – Standardisation request M/575”.
https://ec.europa.eu/growth/tools-databases/enorm/mandate/575_en [Accessed 21 September 2023].

[37] Zvei, “Medical technology needs cybersecurity,” 16 May 2023.
<https://www.zvei.org/presse-medien/publikationen/medizintechnik-braucht-cybersicherheit>

[Accessed 21 September 2023].

[38] E. Biasin, “Medical devices cybersecurity: A growing concern?”, Ku Leuven, 29 September 2019.

<https://www.law.kuleuven.be/citip/blog/medical-devices-cybersecurity-a-growing-concern/>

[Accessed 21 September 2023].

[39] European Commission, “Regulation (EU) 2019/881 of the European Parliament and of the Council,” 17 April 2019.

<https://eur-lex.europa.eu/eli/reg/2019/881/oj> [Accessed 21 September 2023].

[40] European Commission, “Commission Regulation (EU) No 207/2012 on electronic instructions for use (IFU) of medical devices”, *OJ*, vol. 72, p. 28, 9 March 2012.

[41] Johner Institute, “SSRS checklist”.

<https://www.johner-institute.com/ssrs-checklist/> [Accessed 21 September 2023].

[42] MHRA, “MHRA guidance on the health institution exemption (HIE) – IVDR and MDR (Northern Ireland)”, 1 January 2021.

<https://www.gov.uk/government/publications/mhra-guidance-on-the-health-institution-exemption-hie-ivdr-and-mdr-northern-ireland>

[Accessed 21 September 2023].

[43] I3CGlobal, “Person responsible for regulatory compliance”, 3 October 2021.

<https://www.i3cglobal.com/person-responsible-for-regulatory-compliance/>

[Accessed 21 September 2023].

[44] Medical Device Regulation, “MDR: Keep calm and start creating your MDR transition plan”.

<https://www.medical-device-regulation.eu/> [Accessed 21 September 2023].

[45] i3cGlobal, “MDR technical documentation gap analysis”.

<https://www.i3cglobal.com/mdr-technical-file-gap-analysis-checklist/>

[Accessed 21 September 2023].

[46] Greenlight Guru, “SaMD gap assessment tool”.

<https://www.greenlight.guru/eu-mdr-software-medical-device-guidance-audit-gap-tool>

replaces the URL given in the book

[Accessed 27 January 2024].

[47] Advisera, “MDR compliance and how ISO 13485 can with it?”, 9 March 2020.

<https://advisera.com/13485academy/blog/2020/03/09/how-can-iso-13485-help-with-mdr-compliance/>

[Accessed 21 September 2023].

[48] M. Greenaway, “Medical device standards: ISO 13485, ISO 9001 or both?”, 11 May 2020.

<https://www.assentriskmanagement.co.uk/iso-13485-iso-9001-or-both/>

[Accessed 22 September 2023].

[49] E. Bills, “What does EN ISO 14971:2019’s new amendment mean for harmonisation?”, Med Device Online, 4 March 2022.

<https://www.meddeviceonline.com/doc/what-does-en-iso-s-new-amendment-mean-for-harmonisation-0001> [Accessed 22 September 2023].

[50] K. Larsson, “Software hazard identification based on IEC 80002-1 Annex B”, Aligned Elements, 3 May 2021.

<https://www.aligned.ch/blog/product-news/664-software-hazard-identification-from-iec-80002-1-annex-b> [Accessed 22 September 2023].

[51] MDCG, “MDCG 2020-1: Guidance on clinical evaluation (MDR)/performance evaluation (IVDR) of medical device software,” March 2020.

https://health.ec.europa.eu/system/files/2020-09/md_mdcg_2020_5_guidance_clinical_evaluation_equivalence_en_0.pdf

[Accessed 22 September 2023].

[52] MDCG, “MDCG 2020-5: Clinical evaluation - equivalence,” 2020.

https://health.ec.europa.eu/system/files/2020-09/md_mdcg_2020_5_guidance_clinical_evaluation_equivalence_en_0.pdf

[Accessed 22 September 2023].

[53] MDCG, “MDCG 2020-6: Regulation (EU) 2017/745: Clinical evidence needed for medical devices previously CE marked under Directives 93/42/EEC or 90/385/EEC”, April 2020.

https://health.ec.europa.eu/system/files/2020-09/md_mdcg_2020_6_guidance_sufficient_clinical_evidence_en_0.pdf

[Accessed 22 September 2023].

[54] A. Smirthwaite, “Clinical evaluation under EU MDR”, BSI, 2020.

<https://www.bsigroup.com/globalassets/localfiles/en-gb/medical-devices/whitepapers/clinical-evaluation-white-paper/clinical-evaluation-under-eu-mdr.pdf> [Accessed 22 September 2023].

[55] Mantra Systems, “Clinical evaluation reports: CERs for medical devices”, 2021.

<https://www.mantrasystems.co.uk/eu-mdr-compliance/clinical-evaluation-report-cer>

[Accessed 22 September 2023].

[56] World Medical Association, “WMA declaration of Helsinki - Ethical principles for medical research involving human subjects”, 6 September 2022.

<https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/> [Accessed 22 September 2023].

[57] J. Bergsteinsson, “Guide to ISO 14155:2020 for medical devices,” Greenlight Guru, 2020.

<https://www.greenlight.guru/downloads/ultimate-guide-iso-14155-2020-compliant-clinical-investigations> [Accessed 22 September 2023].

[58] European Commission, “Guidance on the content and structure of the summary of the clinical investigation report”, 2023.

[https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52023XC0508\(01\)](https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52023XC0508(01))

[Accessed 22 September 2023].

[59] MDCG, “MDCG 2023-1: Guidance on the Health Institution Exemption under Article 5(5) of Regulation (EU) 2017/745 and Regulation (EU) 2017/746”, January 2023.

https://health.ec.europa.eu/system/files/2023-01/mdcg_2023-1_en.pdf

[Accessed 22 September 2023].

[60] IPeM, “Best-practice guidance for the in-house manufacture of medical devices and non-medical devices, including software in both cases, for use within the same health institution”, 25 July 2022.

<https://www.ipem.ac.uk/media/vp0ewy01/ipembe-1.pdf> [Accessed 22 September 2023].

[61] BSI, “MDR documentation submissions”, May 2020.

<https://www.bsigroup.com/globalassets/meddev/localfiles/fr-fr/ressources/bsi-md-mdr-best-practice-documentation-submissions-en-gb1.pdf> [Accessed 27 January 2024].

[62] K. Cohn, “STED is dead,” Rimsys, 28 December 2022.
<https://www.rimsys.io/blog/sted-is-dead> [Accessed 22 September 2023].

[63] MDCG, “MDCG 2019-9 Rev.1: Summary of safety and clinical performance,” March 2022.
https://health.ec.europa.eu/system/files/2022-03/md_mdcg_2019_9_sscp_en.pdf
[Accessed 22 September 2023].

[64] International Medical Device Regulators Forum, “UDI guidance: Unique Device Identification (UDI) of medical devices”, 18 December 2013.
<https://www.imdrf.org/documents/udi-guidance-unique-device-identification-udi-medical-devices>
[Accessed 21 September 2023].

[65] B. Lentz, “The ultimate guide to the EU MDR/IVDR UDI”, Rimsys, 22 June 2021.
<https://www.rimsys.io/blog/the-ultimate-guide-to-the-eu-mdr-ivdr-udi>
[Accessed 21 September 2023].

[66] European Commission, “MDCG 2018-1 v3 guidance on BASIC UDI-DI and changes to UDI-DI,” 15 March 2020.
<https://ec.europa.eu/docsroom/documents/40322> [Accessed 21 September 2023].

[67] MDCG, “MDCG 2021-19 - Guidance note integration of the UDI within an organisation’s quality management system”, 15 July 2021.
https://health.ec.europa.eu/latest-updates/mdcg-2021-19-guidance-note-integration-udi-within-organisations-quality-management-system-2021-07-15_en [Accessed 21 September 2023].

[68] MDCG, “MDCG 2018-5: UDI assignment to medical device software,” 09 October 2018.
<https://ec.europa.eu/docsroom/documents/31926>. [Accessed 21 September 2023].

[69] H. Lacalle, “UDI for Medical Device Software (MDSW) under EU MDR”, 25 July 2021.
<https://decomplix.com/udi-medical-device-software-mdsw-eu-mdr/>
[Accessed 21 Software 2023].

[70] E. Nichols, “Post-market clinical follow-up under EU MDR: Your guide to PMCF activities,” Greenlight Guru, 10 April 2023.
<https://www.greenlight.guru/blog/post-market-clinical-follow-up>
[Accessed 22 September 2023].

[71] MDCG, “MDCG 2020-7: Post-market clinical follow-up (PMCF) plan template”, April 2020.
https://health.ec.europa.eu/system/files/2020-09/md_mdcg_2020_7_guidance_pmcf_plan_template_en_0.pdf
[Accessed 22 September 2023].

[72] Selecon, “Conformity assessment procedures for medical devices”.
<https://www.selecon.com/en/regulatory-affairs/conformity-assessment-procedures-for-medical-devices/> [Accessed 22 September 2023].

[73] European Commission, “Single market compliance space”.
<https://webgate.ec.europa.eu/single-market-compliance-space/#/home>
[Accessed 22 September 2023].

[74] MDCG, “MDCG 2022-14: MDCG position paper - Notified body capacity and availability of medical devices and IVDs”, August 2022.

https://health.ec.europa.eu/system/files/2022-08/mdcg_2022-14_en.pdf

[Accessed 22 September 2023].

[75] MHRA, “Implementation of the future regulations”, 27 July 2023.

<https://www.gov.uk/government/publications/implementation-of-the-future-regulation-of-medical-devices/implementation-of-the-future-regulations> [Accessed 22 September 2023].

[76] MHRA, “Regulating medical devices in the UK”, 20 July 2023.

<https://www.gov.uk/guidance/regulating-medical-devices-in-the-uk> [Accessed 22 September 2023].

[77] UKMDR, “The medical devices (Amendment) (Great Britain) regulations 2023”, 2023.

<https://ukmdr.com/regulations/> [Accessed 22 September 2023].

[78] Advena, “UK responsible person”.

<https://advenamedical.com/services/uk-responsible-person/> [Accessed 22 September 2023].

[79] MEDDEV, “MEDDEV 2.1/6: Guidelines on the qualification and classification of standalone software used in healthcare within the regulatory framework of medical devices”, 2012.

http://www.meddev.info/_documents/2_1_6_ol_en.pdf [Accessed 24 November 2023].

[80] MHRA, “Guidance on applying human factors to medical devices”, 12 February 2021.

<https://www.gov.uk/government/publications/guidance-on-applying-human-factors-to-medical-devices> [Accessed 22 September 2023].

[81] MedTech Innovation, “The UK Medical Device Information System – A new resource for medtechs”, 31 March 2021.

<https://www.med-technews.com/medtech-insights/medtech-regulatory-insights/the-uk-medical-device-information-system-%E2%80%93-a-new-resource-fo/> [Accessed 22 September 2023].

[82] MHRA, “Register medical devices to place on the market”, 3 August 2023.

<https://www.gov.uk/guidance/register-medical-devices-to-place-on-the-market>

[Accessed 22 September 2023].

[83] UK Department of Health and Social Care, “Independent medicines and medical devices safety review: update report on government implementation”, 22 December 2022.

<https://www.gov.uk/government/publications/independent-medicines-and-medical-devices-safety-review-update-report-on-government-implementation> [Accessed 22 September 2023].

[84] MHRA, “Designated standards: Medical devices,” 6 January 2022.

<https://www.gov.uk/government/publications/designated-standards-medical-devices>

[Accessed 22 September 2023].

[85] NHS England, “Clinical risk management standards”, 27 July 2020.

<https://digital.nhs.uk/services/clinical-safety/clinical-risk-management-standards>

[Accessed 22 September 2023].

[86] NHS England, “Applicability of DCB 0129 and DCB 0160: Step by step guidance”, 4 August 2022.

<https://digital.nhs.uk/services/clinical-safety/applicability-of-dcb-0129-and-dcb-0160/step-by-step-guidance> [Accessed 22 September 2023].

[87] AXREM, “DTAC and DCB 0129 problem statement”, 4 July 2023.

<https://www.axrem.org.uk/axrem-dtac-and-dcb0129-problem-statement/>

[Accessed 22 September 2023].

[88] IPEM, “Clinical risk management foundation course”, 20 June 2023.

https://www.linkedin.com/posts/the-institute-of-physics-and-engineering-in-medicine-ipem-_clinical-risk-management-foundation-course-activity-7063439088007180288-yPQz/

[Accessed 27 January 2024].

[89] IPEM, “Panel discussion: Clinical risk management”, *Scope*, vol. 33, no. 4, pp. 16–19, 2022.

<https://www.ipem.ac.uk/resources/other-resources/?resourceType=2128>

[90] IPEM, “Panel discussion: Clinical risk management - Part 2”. *Scope*, vol. 34, no. 1, pp. 16–19, 2023.

<https://www.ipem.ac.uk/resources/other-resources/?resourceType=2128>

[91] FDA, “Overview of device regulation”, 4 September 2020.

<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/overview-device-regulation> [Accessed 22 September 2023].

[92] B. Sutton, “Overview of regulatory requirements: Medical devices - Transcript”, FDA, November 2011.

<https://www.fda.gov/training-and-continuing-education/cdrh-learn/overview-regulatory-requirements-medical-devices-transcript> [Accessed 22 September 2023].

[93] FDA, “Reclassification”, 31 August 2018.

<https://www.fda.gov/medical-devices/classify-your-medical-device/reclassification>

[Accessed 22 September 2023].

[94] FDA, “The 510(k) program: Evaluating substantial equivalence in premarket notifications [510(k)]”, 28 July 2014.

<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/510k-program-evaluating-substantial-equivalence-premarket-notifications-510k>

<https://www.fda.gov/media/82395/download>

[Accessed 22 September 2023].

[95] FDA, “Premarket approval (PMA)”, 16 May 2019.

<https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-approval-pma> [Accessed 22 September 2023].

[96] FDA, “Classify your medical device”, 7 February 2020.

<https://www.fda.gov/medical-devices/overview-device-regulation/classify-your-medical-device>

[Accessed 22 September 2023].

[97] FDA, “Device classification panels”, 31 August 2018.

<https://www.fda.gov/medical-devices/classify-your-medical-device/device-classification-panels>

[Accessed 22 September 2023].

[98] FDA, “Product classification”.

<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpdc/classification.cfm>

[Accessed 22 September 2023].

- [99] FDA, “CFR - Code of Federal Regulations Title 21”.
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm>
[Accessed 22 September 2023].
- [100] FDA, “Policy for device software functions and mobile medical applications”, 28 September 2022.
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-device-software-functions-and-mobile-medical-applications> [Accessed 22 September 2023].
- [101] FDA, “Medical device data systems, medical image storage devices, and medical image communications devices”, September 2022.
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-device-data-systems-medical-image-storage-devices-and-medical-image-communications-devices>
[Accessed 22 September 2023].
- [102] FDA, “General wellness: Policy for low-risk devices”, September 2019.
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-wellness-policy-low-risk-devices> [Accessed 22 September 2023].
- [103] FDA, “Content of premarket submissions for device software functions”, June 2023.
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-premarket-submissions-device-software-functions>
[Accessed 22 September 2023].
- [104] E. Nichols, “Why class 1 medical device companies need design control”, Greenlight Guru, 12 August 2022.
<https://www.greenlight.guru/blog/class-1-medical-device-design-controls>
[Accessed 27 January 2024].
- [105] M. Shneider, “FDA device approval pathways more complex than ever”, Regulatory Focus, 3 August 2021.
<https://www.raps.org/news-and-articles/news-articles/2021/8/review-fda-device-approval-pathways-more-complex-t> [Accessed 22 September 2023].
- [106] FDA, “510(k) Submission programs”, 12 September 2019.
<https://www.fda.gov/medical-devices/premarket-notification-510k/510k-submission-programs>
[Accessed 22 September 2023].
- [107] FDA, “Premarket notification 510(k),” 3 October 2022.
<https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-notification-510k>
[Accessed 22 September 2023].
- [108] FDA, “How to find and effectively use predicate devices”, 4 September 2018.
<https://www.fda.gov/medical-devices/premarket-notification-510k/how-find-and-effectively-use-predicate-devices> [Accessed 22 September 2023].
- [109] FDA, “FDA issues guidances and requests comments as a part of ongoing efforts to modernize the premarket notification [510(k)] program,” 6 September 2023.
<https://content.govdelivery.com/accounts/USFDA/bulletins/36cccf3>
[Accessed 22 September 2023].

- [110] Drug Watch, “FDA 510(k) clearance process”, 5 September 2023.
<https://www.drugwatch.com/fda/510k-clearance/>
[Accessed 22 September 2023].
- [111] J. Darrow, J. Avorn and A. Kesselheim, “FDA regulation and approval of medical devices: 1976-2020”, *JAMA*, vol. 326, no. 5, pp. 420–432, 2021.
- [112] FDA, “Medical device exemptions 510(k) and GMP requirements”.
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpd/315.cfm>
[Accessed 22 September 2023].
- [113] FDA, “Is a new 510(k) required for a modification to the device?”, 31 October 2017.
<https://www.fda.gov/medical-devices/premarket-notification-510k/new-510k-required-modification-device> [Accessed 22 September 2023].
- [114] FDA, “Product code classification database”, 22 March 2018.
<https://www.fda.gov/medical-devices/classify-your-medical-device/product-code-classification-database> [Accessed 22 September 2023].
- [115] FDA, “510(k) Premarket notification”.
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> [Accessed 22 September 2023].
- [116] FDA, “Content of premarket submissions for device software functions”, June 2023.
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-premarket-submissions-device-software-functions> [Accessed 22 September 2023].
- [117] FDA, “510(k) Third party review program”, 19 August 2022.
<https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/510k-third-party-review-program> [Accessed 22 September 2023].
- [118] FDA, “How to prepare an abbreviated 510(k)”, 23 January 2019.
<https://www.fda.gov/medical-devices/premarket-notification-510k/how-prepare-abbreviated-510k>
[Accessed 22 September 2023].
- [119] FDA, “Format for Traditional and Abbreviated 510(k)s”, 13 September 2019.
https://www.tuvsud.com/ja-jp/-/media/regions/jp/ac/pdf-files/medical-info/2020/11/04_510k_guidance.pdf [Accessed 22 September 2024].
- [120] W. Schroeder, “Special 510(k) vs. Abbreviated 510(k) vs. Traditional 510(k): Which FDA program applies to my device?”, Greenlight Guru, 21 February 2021.
<https://www.greenlight.guru/blog/special-510k-abbreviated-traditional>
[Accessed 23 September 2023].
- [121] FDA, “Refuse to accept policy for 510(k)s”, April 2022.
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/refuse-accept-policy-510ks> [Accessed 22 September 2023].
- [122] J. Speer, “How to avoid being part of the 69% of 510(k) submissions that get rejected the first time”, Greenlight Guru, 15 August 2016.
<https://www.greenlight.guru/blog/how-to-avoid-510-k-submission-rejected>
[Accessed 22 September 2023].
- [123] T. Rish, “How to demonstrate substantial equivalence in 5 easy steps”, 7 March 2021, Greenlight Guru.
<https://www.greenlight.guru/blog/substantial-equivalence> [Accessed 22 September 2023].

[124] J. Speer, “4 Reasons your 510(k) submission will be rejected (and how to avoid them)”, Med Device Online, 19 September 2016.

<https://www.meddeviceonline.com/doc/reasons-your-k-submission-will-be-rejected-and-how-to-avoid-them-0001>

[Accessed 22 September 2023].

[125] FDA, “eCopy medical device submissions”, 3 October 2022.

<https://www.fda.gov/medical-devices/how-study-and-market-your-device/ecopy-medical-device-submissions> [Accessed 23 September 2023].

[126] FDA, “De Novo classification request”, 3 October 2022.

<https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/de-novo-classification-request> [Accessed 23 September 2023].

[127] W. Levine, “FDA PMA submission process: A beginner’s guide”, Rimsys, 27 April 2022.

<https://www.rimsys.io/blog/pma-submission-process-beginners-guide>

[Accessed 23 September 2023].

[128] FDA, “PMA review process”, 13 September 2021.

<https://www.fda.gov/medical-devices/premarket-approval-pma/pma-review-process>

[Accessed 23 September 2023].

[129] FDA, “Breakthrough devices program”, September 2023.

<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/breakthrough-devices-program> [Accessed 23 September 2023].

[130] FDA, “Breakthrough devices program - Metrics”, 30 June 2023.

<https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program#metrics>

[Accessed 23 September 2023].

[131] FDA, “Requests for feedback and meetings for medical device submissions: The Q-submission program”, 2 June 2023.

<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program> [Accessed 23 September 2023].

[132] J. Kasic, “5 Key steps for FDA Q-submissions”, Med Device Online, 18 April 2022.

<https://www.meddeviceonline.com/doc/key-steps-for-fda-q-submissions-0001>

[Accessed 23 September 2023].

[133] US National Archives, “Title 21: Food and drugs”, 21 September 2023.

<https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-820>

[Accessed 23 September 2023].

[134] FDA, “Acceptance of data from clinical investigations for medical devices”, 16 April 2019.

<https://www.fda.gov/medical-devices/investigational-device-exemption-ide/acceptance-data-clinical-investigations-medical-devices> [Accessed 23 September 2023].

[135] FDA, “ISO 14155 Third edition 2020-07”, 21 December 2020.

https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/detail.cfm?standard__identification_no=41711 [Accessed 23 September 2023].

- [136] FDA, “Quality System (QS) regulation/medical device good manufacturing practices”, 22 February 2022.
<https://www.fda.gov/medical-devices/postmarket-requirements-devices/quality-system-qsr-regulationmedical-device-good-manufacturing-practices> [Accessed 23 September 2023].
- [137] FDA, “Guide to inspection of quality systems”, August 1999.
<https://www.fda.gov/media/73166/download> [Accessed 24 September 2023].
- [138] E. Nichols, “Ultimate internal audit checklist: FDA QSR and ISO 13485 audit checklist”, Greenlight Guru, 25 October 2023.
<https://www.greenlight.guru/blog/internal-audit-checklist-medical-device>
[Accessed 26 October 2023].
- [139] E. Nichols, “QMSR explained: What FDA QSR & ISO 13485 harmonization means for medical device companies”, Greenlight Guru, 20 October 2023.
<https://www.greenlight.guru/blog/qmsr-quality-management-system-regulation>
[Accessed 24 November 2023].
- [140] Authenticated US Government Information (GPO), “Federal register: 21 CFR parts 4 and 820”, 23 February 2022.
<https://www.govinfo.gov/content/pkg/FR-2022-02-23/pdf/2022-03227.pdf>
[Accessed 24 September 2023].
- [141] E. Nichols, “ISO 14971 risk management for medical devices: The definitive guide”, Greenlight Guru, 1 September 2023.
<https://www.greenlight.guru/blog/iso-14971-risk-management>
[Accessed 24 September 2023].
- [142] OrielStat, “ISO 14971 and the basics of medical device risk management explained”, 12 January 2024.
<https://www.orielstat.com/blog/iso-14971-risk-management-basics/> [Accessed 14 January 2023].
- [143] FDA, “Deciding when to submit a 510(k) for a software change to an existing device”, October 2017.
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/deciding-when-submit-510k-software-change-existing-device> [Accessed 24 September 2023].
- [144] FDA, “FDASIA health IT report”, 18 November 2020.
<https://www.fda.gov/about-fda/cdrh-reports/fdasia-health-it-report> [Accessed 24 September 2023].
- [145] L. Tsang and V. Pollard, “EU and US regulation of health information technology, software and mobile apps”, Thomson Reuters - Practical Law, 1 August 2014.
<https://uk.practicallaw.thomsonreuters.com/3-518-3154> (abstract, free download upon subscription)
[Accessed 24 September 2023].
- [146] FDA, “General principles of software validation”, 15 May 2019.
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-principles-software-validation> [Accessed 24 September 2023].
- [147] J. Lyons, “CSV vs. CSA: Exploring FDA’s new software validation approach”, Greenlight Guru, 4 June 2023.
<https://www.greenlight.guru/blog/csa-vs-csv> [Accessed 24 September 2023].

[148] FDA, “Computer software assurance for production and quality system software”, September 2022.

<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/computer-software-assurance-production-and-quality-system-software>

[Accessed 24 September 2023].

[149] FDA, “CFR - Code of Federal Regulations title 21 - Part 820”, 7 June 2023.

<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=820.3>

[Accessed 24 September 2023].

[150] J. Lyons, “Beginner’s guide to design verification & design validation for medical devices”, Greenlight Guru, 10 February 2023.

<https://www.greenlight.guru/blog/design-verification-and-design-validation>

[Accessed 24 September 2023].

[151] FDA, “What are examples of Software as a medical device?”, 6 December 2017.

<https://www.fda.gov/medical-devices/software-medical-device-samd/what-are-examples-software-medical-device>

[Accessed 24 September 2023].

[152] J. Smith, “Medical imaging: The basics of FDA regulation”, MD+DI, 1 August 2006.

<https://www.mddionline.com/radiological/medical-imaging-the-basics-of-fda-regulation>

[Accessed 24 September 2023].

[153] FDA, “Developing a software precertification program, v1.0”, January 2019.

<https://www.fda.gov/media/119722/download> [Accessed 24 September 2023].

Also see: Chapter 9, ref [8].

[154] FDA, “Software as a Medical Device (SAMd): Clinical evaluation”, December 2017.

<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/software-medical-device-samd-clinical-evaluation> [Accessed 24 September 2023].

[155] FDA, “Device software functions including mobile medical applications”, 29 September 2022.

<https://www.fda.gov/medical-devices/digital-health-center-excellence/device-software-functions-including-mobile-medical-applications> [Accessed 24 September 2023].

[156] US Federal Trade Commission, “Mobile health app interactive tool”, December 2022.

<https://www.ftc.gov/business-guidance/resources/mobile-health-apps-interactive-tool>

[Accessed 24 September 2023].

[157] FDA, “Clinical decision support software,” 28 September 2022.

<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-decision-support-software> [Accessed 24 September 2023].

[158] FDA, “Technical performance assessment of quantitative imaging in radiological device premarket submissions”, 16 June 2022.

<https://www.fda.gov/media/123271/download> [Accessed 24 September 2023].

[159] FDA, “Computer-assisted detection devices applied to radiology images and radiology device data - Premarket notification [510(k)] submissions”, 28 September 2022.

<https://www.fda.gov/media/77635/download> [Accessed 24 September 2023].

[160] FDA, “Clinical performance assessment: Considerations for computer-assisted detection devices applied to radiology images and radiology device data in premarket notification (510(k)) submissions”, September 2022.
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-performance-assessment-considerations-computer-assisted-detection-devices-applied-radiology>
[Accessed 24 September 2023].

[161] DICOM Director, “What you need to know about the recent FDA device reclassification and medical imaging”, 23 March 2022.
<https://www.dicomdirector.com/recent-fda-device-reclassifications/>
[Accessed 24 September 2023].

[162] RamSoft, “MIMPS and PACS: A quick overview on recent changes from the FDA”, 31 May 2021.
<https://www.ramsoft.com/mimps-and-pacs-a-quick-overview-on-recent-changes-from-the-fda>
[Accessed 24 September 2023].

[163] F. Van Leeuwen, “A 101 guide to the FDA regulatory process for AI radiology software”, Quantib, 20 November 2019.
<https://www.quantib.com/blog/a-101-guide-to-the-fda-regulatory-process-for-ai-radiology-software>
[Accessed 24 September 2023].

[164] FDA, “Division of Standards and Conformity Assessment” (formerly the Standards and Conformity Assessment Program), 24 January 2024.
<https://www.fda.gov/medical-devices/how-study-and-market-your-device/premarket-submissions-selecting-and-preparing-correct-submission> [Accessed 28 January 2024].

[165] FDA, “Recognized consensus standards: Medical devices: IEC 62304”, 14 January 2019.
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfstandards/detail.cfm?standard_identification_no=38829 [Accessed 24 September 2023].

[166] N. Tippmann, “How to leverage IEC 62304 to improve SaMD development processes”, Greenlight Guru, 18 March 2020.
<https://www.greenlight.guru/blog/how-to-leverage-iec-62304-to-improve-samd-development-processes> [Accessed 24 September 2023].

[167] FDA, “Artificial Intelligence and Machine Learning in Software as a Medical Device”, 22 September 2021.
<https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-software-medical-device> [Accessed 24 January 2024].

[168] FDA, “Predetermined Change Control Plans for Machine Learning-Enabled Medical Devices: Guiding Principles”, 24 October 2023.
<https://www.fda.gov/medical-devices/software-medical-device-samd/predetermined-change-control-plans-machine-learning-enabled-medical-devices-guiding-principles>
[Accessed 29 January 2024].

[169] FDA, “Artificial Intelligence and Machine Learning (AI/ML)-enabled medical devices”, 5 October 2022.
<https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-ai-ml-enabled-medical-devices> [Accessed 24 September 2023].

[170] FDA, “FDA authorizes marketing of first cardiac ultrasound software that uses artificial intelligence to guide user”, 7 February 2020.

<https://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-first-cardiac-ultrasound-software-uses-artificial-intelligence-guide-user>

[Accessed 23 September 2023].

[171] FDA, “Applying human factors and usability engineering to medical devices”, February 2016.

<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applying-human-factors-and-usability-engineering-medical-devices>

[Accessed 24 September 2023].

[172] Seleon, “Usability engineering & the IEC 62366-1 for medical devices”, 15 August 2021.

<https://www.seleon.com/en/regulatory-affairs/usability-engineering-the-iec-62366-1-for-medical-devices/> [Accessed 24 September 2023].

[173] FDA, “Human factors: Premarket information - device design and documentation processes”, 10 July 2018.

<https://www.fda.gov/medical-devices/human-factors-and-medical-devices/human-factors-premarket-information-device-design-and-documentation-processes> [Accessed 25 September 2023].

[174] FDA, “Content of human factors information in medical device marketing submissions,” December 2022.

<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-human-factors-information-medical-device-marketing-submissions>

[Accessed 24 September 2023].

[175] FDA, “Guidance on medical device patient labeling”, 31 August 2018.

<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-medical-device-patient-labeling>

[Accessed 24 September 2023].

[176] FDA, “Cybersecurity in medical devices: Quality system considerations and content of premarket submissions”, September 2023.

<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions>

[Accessed 24 September 2023].

[177] IMDRF, “Principles and practices for software bill of materials for medical device cybersecurity”, 13 April 2023.

<https://www.imdrf.org/documents/principles-and-practices-software-bill-materials-medical-device-cybersecurity> [Accessed 24 September 2023].

[178] FDA, “Cybersecurity in medical devices: Refuse to accept policy for cyber devices and related systems under Section 524B of the FD&C Act”, March 2023.

<https://digirepo.nlm.nih.gov/master/borndig/9918662283106676/9918662283106676.pdf>

[Accessed 29 January 2024].

[179] FDA, “Postmarket management of cybersecurity in medical devices”, December 2016.

<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarket-management-cybersecurity-medical-devices> [Accessed 24 September 2023].

[180] IMDRF, “Principles and practices for medical device cybersecurity”, 20 April 2020.

<https://www.imdrf.org/documents/principles-and-practices-medical-device-cybersecurity>

[Accessed 24 September 2023].

[181] FDA, “Labeling - Regulatory requirements for medical devices (FDA 89-4203)”, 31 August 2018.

<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/labeling-regulatory-requirements-medical-devices-fda-89-4203> [Accessed 24 September 2023].

[182] IMDRF, “Label and instructions for use for medical devices”, 16 September 2011.

<https://www.imdrf.org/sites/default/files/docs/ghrf/archived/sg1/technical-docs/ghrf-sg1-n70-2011-label-instruction-use-medical-devices-110916.pdf>

[Accessed 24 September 2023].

[183] Research Collective, “Human factors and FDA: Instructions for use (IFU)”, 15 November 2021.

<https://research-collective.com/fda-medical-device-ifu/> [Accessed 24 September 2023].

[184] FDA, “Acceptable media for electronic product user manuals”, 18 March 2010.

<https://www.fda.gov/media/78332/download> [Accessed 24 September 2023].

[185] FDA, “Device labeling”, 23 October 2020.

<https://www.fda.gov/medical-devices/overview-device-regulation/device-labeling>

[Accessed 24 September 2023].

[186] FDA, “Unique Device Identification System (UDI System)”, 22 July 2022.

<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system> [Accessed 24 September 2023].

[187] US National Archives, “Code of Federal Regulations”, 19 September 2023.

<https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-801/subpart-B>

[Accessed 24 September 2023].

[188] FDA, “Mandatory reporting requirements: Manufacturers, importers and device user facilities”, 22 May 2020.

<https://www.fda.gov/medical-devices/postmarket-requirements-devices/mandatory-reporting-requirements-manufacturers-importers-and-device-user-facilities>

[Accessed 24 September 2023].

[189] FDA, “U.S. agents”, 23 December 2017.

<https://www.fda.gov/medical-devices/device-registration-and-listing/us-agents>

[Accessed 24 September 2023].

[190] Jon Speer, “Here Are the 4 Types of FDA Inspections You Need to Understand”, 6 November 2017.

<https://www.greenlight.guru/blog/types-of-fda-inspections>

[Accessed 29 January 2024]

[190]. QA Consulting, “Overview of the Different Types of FDA Inspections for Medical Devices”, 3 November 2023.

<https://qaconsultinginc.com/types-of-fda-inspections-for-medical-devices/>

[Accessed 20 November 2023]. *This is a replacement for the reference given in the book.*

[191] FDA, “Medical device premarket approval and postmarket inspections - Part III: Inspectional”, 4 December 2017.

<https://www.fda.gov/medical-devices/quality-and-compliance-medical-devices/medical-device-premarket-approval-and-postmarket-inspections-part-iii-inspectional>

[Accessed 24 September 2023].

- [192] S. Silverman, “What you need to know about FDA remote medical device inspections”, MedTechIntelligence, 20 March 2023
<https://medtechintelligence.com/column/what-you-need-to-know-about-fda-remote-medical-device-inspections/> [Accessed 30 January 2024]. *This is a replacement for the reference given in the book.*
- [193] FDA, “Conducting remote regulatory assessments: Q and A’s”, January 2024.
<https://www.fda.gov/media/160173/download> [Accessed 30 January 2024].
- [194] J. Speer, “How to prepare for an FDA inspection”, Greenlight Guru, 5 June 2017.
<https://www.greenlight.guru/blog/how-to-prepare-for-an-fda-inspection>
 [Accessed 24 September 2023].
- [195] FDA, “Review and update of device establishment inspection processes and standards”, 29 June 2020.
<https://www.fda.gov/media/139466/download>.
 [Accessed 24 September 2023].
- [196] MDCG, “MDCG 2021-5: Guidance on standardisation for medical devices” April 2021.
https://health.ec.europa.eu/system/files/2021-04/md_mdcg_2021_5_en_0.pdf
 [Accessed 24 September 2023].
- [197] Med Tech Europe, “Recommendations on the use of guidance documents related to the Medical Device Regulation (MDR) and In vitro Diagnostics Regulation (IVDR)”, 30 June 2022.
<https://www.medtecheurope.org/resource-library/recommendations-on-the-use-of-guidance-documents-related-to-the-medical-device-regulation-mdr-and-in-vitro-diagnostics-regulation-ivdr/>
 [Accessed 24 September 2023].
- [198] Johner Institute, “State of the art: It’s worse than you think”, 11 September 2020.
<https://www.johner-institute.com/articles/regulatory-affairs/and-more/state-of-the-art-its-worse-than-you-think/> [Accessed 24 September 2023].

Chapter 7

- [1] R. Freeman and T. Bischofberger, “Consumer product safety reforms one step closer in Europe”, Cooley, 23 December 2022.
<https://products.cooley.com/2022/12/23/consumer-product-safety-reforms-one-step-closer-in-europe/>
 [Accessed 20 September 2023].
- [2] Office for Product Standards and Safety, “Product safety law: compliance advice for manufacturers and importers”, 20 September 2019.
<https://www.gov.uk/guidance/product-safety-law-compliance-advice-for-manufacturers-and-importers> [Accessed 20 September 2023]. *This replaces the reference given in the book.*
- [3] FME, “MDR guide for medical device software,” 27 September 2021.
<https://www.fme.nl/system/files/publicaties/2021-09/MDR%20Guide.pdf>
 [Accessed 20 September 2023].
- [4] J. K. Barchie, “What is GDPR’s effect on medical devices”, Med Device Online, 30 April 2018.
<https://www.meddeviceonline.com/doc/what-is-gdpr-s-effect-on-medical-devices-0001>
 [Accessed 20 September 2023].

- [5] P. Cosgriff and J. Åtting, “Regulatory considerations when deploying your software in a clinical environment”, in *Diagnostic Radiology Physics with MATLAB*, London: CRC Press, 2021, pp. 121–125.
- [6] European Medicines Agency, “National competent authorities (human)”.
<https://www.ema.europa.eu/en/partners-networks/eu-partners/eu-member-states/national-competent-authorities-human> [Accessed 20 September 2023].
- [7] A. Krause, O. Becker, “Liability for software under the current Product Liability Directive”, 18 March 2022.
<https://www.linklaters.com/en/insights/blogs/productliabilitylinks/2022/march/liability-for-software-under-the-current> [Accessed 20 September 2023].
- [8] J. Leadley, K. Corby, J. Redmond and L. Gest, “EU: Modernised Product Liability Directive proposal finally arrives”, Baker McKenzie InsightPlus, 10 October 2022.
https://insightplus.bakermckenzie.com/bm/consumer-goods-retail_1/eu-modernised-product-liability-directive-proposal-finally-arrives [Accessed 20 September 2023].
- [9] European Union, “Proposal for a DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on liability for defective products”, 28 September 2022.
<https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A52022PC0495>
[Accessed 20 September 2023].
- [10] R. Freeman, C. Temple, C. Bischofberger, S. Dobson and C. Roberts, “Product liability and safety in the EU: Overview”, 01 August 2020.
<https://uk.practicallaw.thomsonreuters.com/w-013-0379> (Abstract, full text available on subscription to Practical law). [Accessed 20 November 2023].
- [11] LexisNexis, “‘Development risks’ or ‘state of the art’ defence to defective product liability”.
<https://www.lexisnexis.co.uk/legal/commentary/efp/sale-of-goods-vol-34/387-development-risks-or-state-of-the-art-defence-to-defective-product-liability> (Abstract, full text available on subscription to LexisNexis). [Accessed 20 November 2023].
- [12] MedTech Europe, “Product liability rules and the medical technology sector”, 07 July 2022.
https://www.medtecheurope.org/wp-content/uploads/2022/09/20220712_position-paper_final.pdf
[Accessed 20 September 2023].
- [13] S. Seubert, “Product liability: Medical device manufacturers pay attention!”, Johner Institute, 11 February 2021.
<https://www.johner-institute.com/articles/regulatory-affairs/and-more/product-liability/>
[Accessed 20 September 2023].
- [14] European Union, “Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL LAYING DOWN HARMONISED RULES ON ARTIFICIAL INTELLIGENCE (ARTIFICIAL INTELLIGENCE ACT) AND AMENDING CERTAIN UNION LEGISLATIVE ACTS”, 21 April 2021.
<https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A52021PC0206>
[Accessed 20 September 2023].
- [15] European Parliament, “EU AI Act: First regulation on artificial intelligence”, 19 December 2023.
<https://www.europarl.europa.eu/news/en/headlines/society/20230601STO93804/eu-ai-act-first-regulation-on-artificial-intelligence> [Accessed 30 January 2024].

- [16] European Commission, “White paper on artificial intelligence: A European approach to excellence and trust”, 19 February 2020.
https://commission.europa.eu/publications/white-paper-artificial-intelligence-european-approach-excellence-and-trust_en [Accessed 20 September 2023].
- [17] MedTech Europe, “MedTech Europe’s reaction to the EU Council’s General Approach on the AI Act”, 7 December 2022.
<https://www.medtecheurope.org/resource-library/medtech-europes-reaction-to-the-eu-councils-general-approach-on-the-ai-act/> [Accessed 18 September 2023].
- [18] Congressional Research Service, “Enforcement of the food, drug, and cosmetic act: Select legal issues”, 09 February 2018.
<https://crsreports.congress.gov/product/pdf/R/R43609> [Accessed 20 September 2023].
- [19] S. E. Dyson, “Medical device software & products liability: An overview (Part I) - MedTech Intelligence”, MedTech Intelligence, 15 September 2017.
https://medtechintelligence.com/feature_article/medical-device-software-products-liability-overview-part/ [Accessed 20 September 2023].
- [20] S. E. Dyson, “Medical device software & products liability: The homefront (Part II) - MedTech Intelligence”, MedTech Intelligence, 27 November 2017.
https://medtechintelligence.com/feature_article/medical-device-software-products-liability-homefront-part-ii/ [Accessed 20 September 2023].
- [21] Barbara J. Evans and Frank Pasquale, “Product liability suits for FDA-regulated AI/ML software”, In: *The Future of Medical Device Regulation*, Cambridge University Press, Cambridge, UK, 2022, pp. 22–35.
- [22] Cornell Law School, “Negligence”, Legal Information Institute.
<https://www.law.cornell.edu/wex/negligence> [Accessed 20 September 2023].
- [23] K. Crobar, “General wellness v. medical device considerations”, NYS Science & Technology Law Center, Syracuse University, 09 April 2021.
<https://nysstlc.syr.edu/general-wellness-v-medical-device-considerations/> [Accessed 20 September 2023].
- [24] Medicines & Healthcare Products Regulatory Agency, “Medical devices: The regulations and how we enforce them”, 01 July 2023.
<https://www.gov.uk/government/publications/report-a-non-compliant-medical-device-enforcement-process/how-mhra-ensures-the-safety-and-quality-of-medical-devices> [Accessed 20 September 2023].
- [25] Which? “Consumer Protection Act 1987”, 04 August 2022.
<https://www.which.co.uk/consumer-rights/regulation/consumer-protection-act-1987-a5xTL3w6L9OI> [Accessed 20 September 2023].
- [26] S. Silver, I. Hobbs, P. Margolis and M. Naidoo, “Chambers UK: Product Liability & Safety 2021 - Trends and developments”, Kennedys Law, 28 June 2021.
<https://kennedyslaw.com/en/thought-leadership/article/chambers-uk-product-liability-safety-2021-trends-and-developments/> [Accessed 20 September 2023].
- [27] Thomson Reuters, “Negligence”, Practical Law.
<https://uk.practicallaw.thomsonreuters.com/0-107-6876> (Abstract, full text available on subscription to Practical Law) [Accessed 20 November 2023].
- [28] National Accident Healthline, “What is medical negligence?”.

<https://www.national-accident-helpline.co.uk/medical-negligence/what-is-medical-negligence>
[Accessed 20 September 2023].

[29] NHS Indemnity, “Arrangements for clinical negligence claims in the NHS”.
<https://resolution.nhs.uk/wp-content/uploads/2018/10/NHS-Indemnity.pdf>
[Accessed 20 September 2023].

[30] The Stationary Office, “Consumer Rights Act 2015 - Explanatory notes”, 2015.
<https://www.legislation.gov.uk/ukpga/2015/15/notes/annex/2#>.
[Accessed 20 September 2023].

[31] A. Sanders, “Vicarious liability - The UK Supreme Court hands down two important decisions”, Global Workplace Insider, Norton Rose Fulbright, 02 April 2020.
<https://www.globalworkplaceinsider.com/2020/04/vicarious-liability-the-uk-supreme-court-hands-down-two-important-decisions/> [Accessed 20 September 2023].

[32] NHS Resolution, “Clinical negligence scheme for trusts - NHS resolution”.
<https://resolution.nhs.uk/services/claims-management/clinical-schemes/clinical-negligence-scheme-for-trusts/> [Accessed 20 September 2023].

[33] Scottish Government, “A study of medical negligence claiming in Scotland”, 07 June 2012.
<https://www.gov.scot/publications/study-medical-negligence-claiming-scotland/pages/2/>
[Accessed 20 September 2023].

[34] Institute of Physics and Engineering in Medicine, “Code of professional and ethical conduct”, 25 January 2018.
<https://www.ipem.ac.uk/media/ogripbyz/03-07-05-0217-08-00-code-of-professional-and-ethical-conduct.pdf> [Accessed 23 September 2023].

[35] American Association of Physicists in Medicine, “AP 128-A: Code of Ethics for the American Association of Physicists in Medicine”, 19 November 2020.
<https://www.aapm.org/org/policies/details.asp?id=2564&type=AP#Section2>
[Accessed 20 September 2023]. *This replaces the URL given in the book.*

[36] IPeM, “Best-practice guidance for the in-house manufacture of medical devices and non-medical devices, including software in both cases, for use within the same health institution”, 25 July 2022.
<https://www.ipem.ac.uk/media/vp0ewy01/ipembe-1.pdf> [Accessed 22 September 2023].

[37] International Society for Pharmaceutical Engineering, “Pharmaceutical facility publications and guidance documents”.
<https://ispe.org/publications/guidance-documents> [Accessed 20 September 2023].

[38] L. Fraser, N. Parkar, K. Adamson et al, “Guidance on medical physics expert support for nuclear medicine”, *The British Journal of Radiology*, vol. 95, no. 1135, 2022.

[39] C. Caruana, S. Christofides and G. Hartmann, “European Federation of Organisations for Medical Physics (EFOMP) policy statement 12.1: Recommendations on medical physics education and training in Europe 2014”, *Physica Medica*, vol. 30, no. 6, pp. 598–603, 2014.

[40] L. Hadjiiski, “AAPM task group report 273: Recommendations on best practices for AI and machine learning for computer-aided diagnosis in medical imaging”, *Medical Physics*, vol. 50, no. 2, pp. e1–e24, 2022.

[41] M. Miquel, “Copyright revisited,” *Scope*, vol. 20, no. 1, pp. 12–17, 2011.
<https://www.ipem.ac.uk/resources/other-resources/?resourceType=2128>

- [42] NHS Innovation Service, “Your gateway to innovation in the NHS”.
<https://innovation.nhs.uk/> [Accessed 20 September 2023].
- [43] S. K. Peterson, “What’s the difference between open-source software and free software?”,
opensource.com, 7 November 2017.
<https://opensource.com/article/17/11/open-source-or-free-software>
[Accessed 20 September 2023].
- [44] Medicines & Healthcare Products Regulatory Agency, “MHRA software flowchart”.
https://assets.publishing.service.gov.uk/media/64a7d22d7a4c230013bba33c/Medical_device_stand-alone_software_including_apps_including_IVDMDs_.pdf [Accessed 20 September 2023].
- [45] S. Mahawar, “Intellectual property issues relating to open-source software”, iPleaders, 18 March 2022.
<https://blog.ipleaders.in/intellectual-property-issues-relating-open-source-software/>
[Accessed 20 September 2023].
- [46] Open Source Initiative, “Licenses”.
<https://opensource.org/license/> [Accessed 20 September 2023].
- [47] Civic Commons, “Contributor agreements: How to accept code and documentation contributions legally”, Wiki, 25 January 2015.
https://wiki.civiccommons.org/Contributor_Agreements/ [Accessed 22 September 2023].
- [48] Apache Software Foundation, “ASF contributor agreements”.
<https://www.apache.org/licenses/contributor-agreements.html> [Accessed 20 September 2023].
- [49] Synopsys, “Guide to open-source licenses”, 05 October 2016.
<https://www.synopsys.com/blogs/software-security/open-source-licenses.html>
[Accessed 20 September 2023].
- [50] T. Holwerda, “The difference between EULAs and open source licenses”, OSnews, 25 September 2009.
<https://www.osnews.com/story/22233/the-difference-between-eulas-and-open-source-licenses/>
[Accessed 20 September 2023].
- [51] S. Morrison, “Quality Considerations of Open-Source Software for Medical Devices”, Siemens, 17 January 2022.
<https://blogs.sw.siemens.com/embedded-software/2022/01/17/quality-considerations-of-open-source-software-for-medical-devices/> [Accessed 20 September 2023].
- [52] K. MacCallum, “Should you use Open Source Software in Medical Devices?”, StarFish Medical, 19 March 2018.
<https://starfishmedical.com/blog/open-source-software-medical-devices/>
[Accessed 20 September 2023].
- [53] C. Eastham, “Is open source technology the healthy option for medical devices?”, Fieldfisher, 11 November 2022.
<https://www.fieldfisher.com/en/insights/is-open-source-technology-the-healthy-option-for-medical-devices> [Accessed 20 September 2023].

Chapter 8

[1] D. Wilkerson, “2023 predictions for medical device product development”. Jama Software, 22 December 2022.

<https://www.jamasoftware.com/blog/2023-predictions-for-medical-device-product-development>
[Accessed 19 September 2023].

[2] NHS, “NHS long term plan”.

<https://www.longtermplan.nhs.uk/> [Accessed 19 September 2023].

[3] National Health Executive, “WannaCry cyber-attack cost the NHS £92m after 19,000 appointments were cancelled”, 12 October 2018

<https://www.nationalhealthexecutive.com/articles/wannacry-cyber-attack-cost-nhs-ps92m-after-19000-appointments-were-cancelled> [Accessed 19 September 2023].

[4] A. Flavin, E. O’Toole and L. Murphy, “A national cyberattack affecting radiation therapy: The Irish experience”, *Advances in Radiation Oncology*, vol. 7, no. 5, pp. 2452-1094, 2022.

[5] BlackBerry, “BlackBerry quarterly global threat report 2023”, November 2023.

<https://www.blackberry.com/us/en/solutions/threat-intelligence/threat-report>
[Accessed 19 November 2023].

[6] ENISA, “Definition of cybersecurity - Gaps and overlaps in standardisation”, 1 July 2016.

<https://www.enisa.europa.eu/publications/definition-of-cybersecurity>
[Accessed 19 September 2023].

[7] Medical Device Coordination Group, “MDCG 2019-16 - Guidance on cybersecurity for medical devices”, 06 January 2020.

<https://ec.europa.eu/docsroom/documents/41863> [Accessed 19 September 2023].

[8] S. Domas, “Balancing cybersecurity and interoperability in medical devices”, Med Device Online, 26 May 2017.

<https://www.meddeviceonline.com/doc/balancing-cybersecurity-and-interoperability-in-medical-devices-0001> [Accessed 19 September 2023].

[9] B. Lutkevich and A. DelVecchio, “What is the Internet of Medical Things (IoMT)? | Definition from TechTarget”, TechTarget, March 2023.

<https://www.techtarget.com/iotagenda/definition/IoMT-Internet-of-Medical-Things>
[Accessed 19 September 2023].

[10] Deloitte, “Medtech and the internet of medical things”, Deloitte, July 2018.

<https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-medtech-iomt-brochure.pdf>
[Accessed 19 September 2023].

[11] Skyhigh Security, “Cloud computing security issues”.

<https://www.skyhighsecurity.com/cybersecurity-defined/cloud-computing-security-issues.html>
[Accessed 19 September 2023].

[12] International Medical Device Regulators Forum, “Principles and practices for medical device cybersecurity | International Medical Device Regulators Forum”, 20 April 2020.

<https://www.imdrf.org/documents/principles-and-practices-medical-device-cybersecurity>

[Accessed 19 September 2023].

[13] Food and Drug Administration, “Cybersecurity in medical devices: Quality system considerations and content of premarket submissions | FDA”, September 2023.
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions>
[Accessed 19 September 2023].

[14] National (UK) Cyber Security Centre, “Risk management”, 09 June 2023.
<https://www.ncsc.gov.uk/collection/risk-management>
[Accessed 19 September 2023].

[15] National Cyber Security Centre, “Threat modelling - NCSC.GOV.UK”, 09 June 2023.
<https://www.ncsc.gov.uk/collection/risk-management/threat-modelling>
[Accessed 19 September 2023].

[16] AAMI, “AAMI TIR97:2019 (R2023) - Principles for medical device security - Postmarket risk management for device manufacturers”, 27 September 2019.
<https://webstore.ansi.org/standards/aami/aamitir972019r2023> [Accessed 19 September 2023].

[17] D. Tran, “Best practice for secure software development”, 31 March 2023.
<https://www.perforce.com/blog/sca/best-practices-secure-software-development>
[Accessed 19 September 2023].

[18] Ø. Forsbak, “10 Best practices for software development security”, Orient, 29 November 2021.
<https://www.orientsoftware.com/blog/software-development-security/>
[Accessed 19 September 2023].

[19] Food and Drug Administration, “Cybersecurity for networked medical devices containing Off-the-Shelf (OTS) software,” 2 February 2018
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-networked-medical-devices-containing-shelf-ots-software> [Accessed 19 September 2023].

[20] J. Martin, “A guide to standard SBOM formats”, mend.io, 04 May 2023.
<https://www.mend.io/blog/guide-to-standard-sbom-formats/>
[Accessed 19 September 2023].

[21] E. Kaminski, “The FDA drops a cybersecurity compliance SBOM in 2023- Cybersecurity best practice and SBOM guidance for medical devices”, Ketryx, 9 July 2023.
<https://www.ketryx.com/blog/fda-drops-an-sbom> [Accessed 19 September 2023].

[22] ENISA, “Cybersecurity of AI and standardisation”, 14 March 2023.
<https://www.enisa.europa.eu/publications/cybersecurity-of-ai-and-standardisation>
[Accessed 19 September 2023].

Chapter 9

[1] M. Andreessen, “Why software is eating the World”, 20 August 2011.
<https://a16z.com/why-software-is-eating-the-world/> [Accessed 10 September 2023]

- [2] Medical Device Innovation Consortium, “Medical Device Innovation Consortium Regulatory Science Advancement,” Medical Device Innovation Consortium, 18 September 2023.
<https://mdic.org/> [Accessed 18 September 2023].
- [3] Food and Drug Administration, “Fostering medical device improvement: FDA activities and engagement with the voluntary improvement program”, 15 September 2023.
<https://www.fda.gov/media/158180/download> [Accessed 18 September 2023].
- [4] Food and Drug Administration, “Medical devices; Quality system regulation amendments”, *Federal Register*, vol. 87, no. 36, pp. 10119–10134, 23 February 2022.
- [5] G. Ramaley, “Quality Digest - It’s time for the FDA to fully embrace ISO 13485”, *Quality Digest*, 16 August 2022.
<https://www.qualitydigest.com/inside/healthcare-column/it-s-time-fda-fully-embrace-iso-13485-081622.html> [Accessed 2023 September 2023].
- [6] E. Nichols, “AAMI TIR45: Closing the gap between agile software development & medical device regulations”, *Greenlight Guru*, 11 September 2022.
<https://www.greenlight.guru/blog/aami-tir45> [Accessed 18 September 2023].
- [7] F. Al-Faruque, “FDA acknowledges shortcomings of Pre-Cert pilot in report”, *Regulatory focus*, Regulatory Affairs Professionals Society (RAPS), 03 October 2022.
<https://www.raps.org/News-and-Articles/News-Articles/2022/10/FDA-acknowledges-shortcomings-of-Pre-Cert-pilot-in> [Accessed 18 September 2023].
- [8] Food and Drug Administration, “The Software Precertification (Pre-Cert) Pilot Program: Tailored total product lifecycle approaches and key findings”, September 2022.
<https://www.fda.gov/medical-devices/digital-health-center-excellence/digital-health-software-precertification-pre-cert-pilot-program> or
<https://www.fda.gov/media/161815/download> (direct to pdf).
[Accessed 18 September 2023].
- [9] T. Hwang, A. Kesselheim and K. Vokinger, “Lifecycle regulation of artificial intelligence and machine learning-based software devices in medicine”, *JAMA*, vol. 322, no. 23, pp. 2285–2286, 2019.
- [10] R. Parikh, Z. Obermeyer and A. Navathe, “Regulation of predictive analytics in medicine”, *Science*, vol. 363, no. 6429, pp. 810–812, 2019.
- [11] FDA, “Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning (AI/ML)-based Software as a Medical Device (SaMD)”, 04 February 2019.
<https://www.fda.gov/files/medical%20devices/published/US-FDA-Artificial-Intelligence-and-Machine-Learning-Discussion-Paper.pdf> [Accessed 18 September 2023].
- [12] Food and Drug Administration, “Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan”, January 2021.
<https://www.fda.gov/media/145022/download> [Accessed 18 September 2023].
For more background to the report, see:
<https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-software-medical-device> [Accessed 1 February 2024].
- [13] Food and Drug Administration, “Marketing submission recommendations for a predetermined change control plan for Artificial Intelligence/Machine Learning (AI/ML) - enabled device software functions”, 03 April 2023.
<https://www.fda.gov/media/166704/download> [Accessed 18 September 2023].

- [14] European Commission, “MDCG 2022-14 - Transition to the MDR and IVDR - Notified body capacity and availability of medical devices and IVDs”, 26 August 2022.
https://health.ec.europa.eu/system/files/2022-08/mdcg_2022-14_en.pdf
[Accessed 18 September 2023].
- [15] European Commission, “Guidance on qualification and classification of software in regulation (EU) 2017/745 – MDR and regulation (EU) 2017/746 – IVDR”, 10 October 2019.
<https://ec.europa.eu/docsroom/documents/37581>
[Accessed 18 September 2023].
- [16] R. De La Cruz, “The application of IEC 62304 for AI and other technologies: It’s not rocket science, it’s computer science”, AAMI Array, 13 February 2023.
<https://array.aami.org/content/news/application-iec-62304-ai-and-other-technologies-s-not-rocket-science-s-computer-science> [Accessed 18 September 2023].
- [17] U. Muchlematter, P. Daniore and K. Vokinger, “Approval of artificial intelligence and machine learning-based medical devices in the USA and Europe (2015–20): A comparative analysis”, *Lancet Digital Health*, vol. 3, no. 3, pp. e195–e203, 2021.
- [18] European Commission, “Draft standardisation request to the European Standardisation Organisations in support of safe and trustworthy artificial intelligence”, 05 December 2022.
<https://ec.europa.eu/docsroom/documents/52376> [Accessed 18 September 2023].
- [19] MedTech Europe, “MedTech Europe’s reaction to the EU Council’s general approach on the AI Act”, MedTech Europe, 07 December 2022.
<https://www.medtecheurope.org/resource-library/medtech-europes-reaction-to-the-eu-councils-general-approach-on-the-ai-act/> [Accessed 18 September 2023].
- [20] European Parliamentary Research Service, “Artificial intelligence in healthcare - Applications, risks, and ethical and societal impacts”, June 2022.
[https://www.europarl.europa.eu/RegData/etudes/STUD/2022/729512/EPRS_STU\(2022\)729512_EN.pdf](https://www.europarl.europa.eu/RegData/etudes/STUD/2022/729512/EPRS_STU(2022)729512_EN.pdf) [Accessed 18 September 2023].
- [21] P. Rudd-Clarke and A. Lundy, “The UK medical devices regime and the impact of the Northern Ireland Protocol”, Osborne Clarke, 22 July 2022.
<https://www.osborneclarke.com/insights/uk-medical-devices-regime-and-impact-northern-ireland-protocol> [Accessed 18 September 2023].
- [22] Department of Health and Social Care, “Consultation on the future regulation of medical devices in the United Kingdom”, 26 June 2022.
<https://www.gov.uk/government/consultations/consultation-on-the-future-regulation-of-medical-devices-in-the-united-kingdom> [Accessed 18 September 2023].
- [23] Medicines & Healthcare Products Regulatory Agency, “Implementation of the future regulations”, 27 January 2024.
<https://www.gov.uk/government/publications/implementation-of-the-future-regulation-of-medical-devices/implementation-of-the-future-regulations> [Accessed 2 February 2024].
This replaces the URL given in the book.
- [24] UK House of Commons, “Medical technology regulations and the NHS”, 27 March 2023.
<https://commonslibrary.parliament.uk/research-briefings/cdp-2023-0077/>
[Accessed 18 September 2023].
- [25] Department of Health and Social Care, “Software and AI as a medical device change programme - Roadmap”, 14 June 2023.

<https://www.gov.uk/government/publications/software-and-ai-as-a-medical-device-change-programme/software-and-ai-as-a-medical-device-change-programme-roadmap>
[Accessed 18 September 2023].

[26] Department for Health and Social Care, “Regulatory horizons council: The regulation of artificial intelligence as a medical device”, 30 November 2022.
<https://www.gov.uk/government/publications/regulatory-horizons-council-the-regulation-of-artificial-intelligence-as-a-medical-device> [Accessed 18 September 2023].

[27] HM Government, “Regulatory Horizons Council (RHC)”, July 2023.
<https://www.gov.uk/government/groups/regulatory-horizons-council-rhc>
[Accessed 18 September 2023].

[28] Department for Science, Innovation and Technology, “A pro-innovation approach to AI regulation”, 3 August 2023.
<https://www.gov.uk/government/publications/ai-regulation-a-pro-innovation-approach/white-paper>
[Accessed 18 September 2023].

[29] NHS Artificial Intelligence Laboratory, “The NHS AI Lab”.
<https://transform.england.nhs.uk/ai-lab/> [Accessed 18 September 2023].

[30] Medicines & Healthcare Products Regulatory Agency, “Software and Artificial Intelligence (AI) as a medical device”, 25 October 2023.
<https://www.gov.uk/government/publications/software-and-artificial-intelligence-ai-as-a-medical-device/software-and-artificial-intelligence-ai-as-a-medical-device> [Accessed 26 October 2023].

[31] Medicines & Healthcare Products Regulatory Agency, “Consultation on the future regulation of medical devices in the United Kingdom”, 26 June 2022.
<https://www.gov.uk/government/consultations/consultation-on-the-future-regulation-of-medical-devices-in-the-united-kingdom> [Accessed 18 September 2023].

[32] Johner Institute.
<https://www.johner-institute.com/> [Accessed 18 September 2023].

[33] Greenlight Guru.
<https://www.greenlight.guru/blog> [Accessed 18 September 2023].

[34] International Medical Device Regulators Forum, “About IMDRF - International Medical Device Regulators Forum”.
<https://www.imdrf.org/about> [Accessed 18 September 2023].

[35] FDA, “International Medical Device Regulators Forum (IMDRF)”.
<https://www.fda.gov/medical-devices/cdrh-international-affairs/international-medical-device-regulators-forum-imdrf>
[Accessed 18 September 2023].

[36] International Medical Device Regulators Forum, “Working Groups | International Medical Device Regulators Forum (IMDRF)”.
<https://www.imdrf.org/working-groups> [Accessed 18 September 2023].

[37] International Medical Device Regulators Forum, “IMDRF Strategic Plan 2021–2025”.
<https://www.imdrf.org/documents/imdrf-strategic-plan-2021-2025>
[Accessed 18 September 2023].

[38] International Medical Device Regulators Forum, “IMDRF Strategic Plan 2021–2025 -

Progress Report Card”.

<https://www.imdrf.org/documents/imdrf-strategic-plan-2021-2025-progress-report-card>

[Accessed 18 September 2023].

[39] Johner Institute, “7 tips for the successful digital transformation of medical device manufacturers”, 1 June 2023.

<https://www.johner-institut.de/blog/gesundheitswesen/digitale-transformation/>

[Accessed 18 September 2023].

[40] Johner Institute, “Real-time Compliance System (RCS)”.

<https://www.johner-institut.de/produkte/realtime-compliance-system/>

[Accessed 18 September 2023].

[41] Johner Institute, “Regulatory intelligence - A core task of regulatory affairs?”, 28 June 2023.

<https://www.johner-institute.com/articles/regulatory-affairs/regulatory-intelligence/>

[Accessed 18 September 2023].

[42] Johner Institute, “Regulation as code: The end of regulation as we know it”.

<https://www.johner-institute.com/articles/regulatory-affairs/regulations-as-code/>

[Accessed 18 September 2023].

[43] L. Eadicicco, “Fitbit and Apple know their smartwatches aren’t medical devices. But do you?”, CNET, 14 January 2022.

<https://www.cnet.com/tech/mobile/features/fitbit-apple-know-smartwatches-arent-medical-devices-but-do-you/> [Accessed 18 September 2023].

[44] Apple Inc., “Healthcare - Apple watch - Apple”.

<https://www.apple.com/healthcare/apple-watch/> [Accessed 18 September 2023].

[45] Apple Inc., “Apple watch series 8 - Technical specifications”, 2022.

https://support.apple.com/kb/SP878?viewlocale=en_GB&locale=en_GB

[Accessed 18 November 2023].

[46] H. Yu, “Regulation of digital health technologies in the European Union”, in *The Future of Medical Device Regulation*, Cambridge, Cambridge University Press, 2022, pp. 103–114.

[47] T. Bowe, “Demystifying the nuances of AI & ML for your regulated medical product”, Med Device Online, 14 June 2023.

<https://www.meddeviceonline.com/doc/demystifying-the-nuances-of-ai-ml-for-your-regulated-medical-product-0001> [Accessed 18 September 2023].

[48] K. Pretz, “Stop calling everything AI, machine-learning pioneer says”, IEEE Spectrum, 31 March 2021.

<https://spectrum.ieee.org/stop-calling-everything-ai-machinelearning-pioneer-says>

[Accessed 18 September 2023].

[49] US Government, “The National Artificial Intelligence Initiative (NAII)”.

<https://ai.gov/> [Accessed 18 September 2023].

[50] American Medical Association (AMA), “Augmented intelligence in medicine”.

<https://www.ama-assn.org/practice-management/digital/augmented-intelligence-medicine>

[Accessed 18 September 2023].

[51] International Medical Device Regulators Forum, “Machine learning-enabled medical devices: Key terms and definitions”, 09 May 2022.

<https://www.imdrf.org/documents/machine-learning-enabled-medical-devices-key-terms-and-definitions> [Accessed 18 September 2023].

[52] M. Vockley, “AAMI releases special report on Artificial Intelligence”, AAMI Array, 13 April 2023.

<https://array.aami.org/content/news/aami-releases-special-report-artificial-intelligence> [Accessed 18 September 2023].

[53] European Union Agency for Cybersecurity, “Cybersecurity of AI and standardisation,” 14 March 2023.

<https://www.enisa.europa.eu/publications/cybersecurity-of-ai-and-standardisation> [Accessed 18 September 2023].

[54] J. Worth, “Stop calling it Artificial Intelligence”, 02 October 2016.

<https://joshworth.com/stop-calling-in-artificial-intelligence/> [Accessed 18 September 2023].

[55] IFPI, “European creators and right holders call for meaningful transparency obligations on AI systems to ensure the lawful use of copyright-protected content”, 19 July 2023.

<https://www.ifpi.org/european-creators-and-right-holders-call-for-meaningful-transparency-obligations-on-ai-systems-to-ensure-the-lawful-use-of-copyright-protected-content/>

[Accessed 18 September 2023].

[56] K. Kato, “Regulatory process of artificial intelligence”, Pharmaceuticals and Medical Device Agency (Japan), 1 March 2023.

<https://www.pmda.go.jp/files/000226223.pdf> [Accessed 18 September 2023].

[57] K. Chinzei, “Regulatory science on AI-based medical devices and systems”, *Advanced Biomedical Engineering*, vol. 7, pp. 118–123, 2018.

[58] S. Beale, “Small regulatory steps for AI in SaMD”, Med Device Online, 28 December 2021.

<https://www.meddeviceonline.com/doc/small-regulatory-steps-for-ai-in-samd-0001>

[Accessed 18 September 2023].

[59] H. Chen, C. Gomez and C. Huang, “Explainable medical imaging AI needs human-centered design: Guidelines and evidence from a systematic review”, *NPJ Digital Medicine*, vol. 5, p. 156, 2022.

[60] S. Ready, “Explainability and artificial intelligence in medicine”, *The Lancet Digital Health*, vol. 4, no. 4, pp. E214–E215, 2022.

[61] B. Solaiman and M. Bloom, “AI, explainability, and safeguarding patient safety in Europe”, in *The Future of Medical Device Regulation*, Cambridge, Cambridge University Press, 2022, pp. 91-102.

[62] V. Turri, “What is explainable AI?”, Carnegie Mellon University - Software Engineering Institute, 17 January 2022.

<https://insights.sei.cmu.edu/blog/what-is-explainable-ai/> [Accessed 18 September 2023].

[63] The Lancet Digital Health, “The false hope of current approaches to explainable artificial intelligence in health care”, *The Lancet Digital Health*, vol. 3, no. 11, pp. E745-E750, 2021.

[64] World Health Organisation, “Ethics and governance of artificial intelligence for health”, 28 June 2021.

<https://www.who.int/publications/i/item/9789240029200> [Accessed 18 September 2023].

[65] J. R. Geis, “Ethics of artificial intelligence in radiology: Summary of the joint European

and North American multisociety statement”, *Radiology*, vol. 293, no. 2, pp. 436–440, 2019.

[66] A. Aristidou, R. Jena and E. Topol, “Bridging the chasm between AI and clinical implementation”, *The Lancet*, vol. 399, no. 10325, pp. 12–18, 2022.

[67] C. McCague, “Position statement on clinical evaluation of imaging AI”, *The Lancet Digital Health*, vol. 5, no. 7, pp. e400–e402, 2023.

[68] R. Parikh, Z. Obermeyer and A. Navathe, “Regulation of predictive analytics in medicine”, *Science*, vol. 363, no. 6429, pp. 810–812, 2019.

[69] AMA-ASSN, “2018 AI Board report summary”, 2019.

<https://www.ama-assn.org/system/files/2019-08/ai-2018-board-policy-summary.pdf>

[Accessed 18 September 2023].

[70] D. Tietjen and E. Schwind, “AI software ChatGPT – Actually a medical device?”, Taylor Wessing, 27 March 2023.

<https://www.taylorwessing.com/en/insights-and-events/insights/2023/03/ki-software-chatgpt>

[Accessed 18 September 2023].

[71] The Lancet Digital Health, “ChatGPT: Friend or foe?”, *The Lancet Digital Health*, vol. 5, no. 3, E102, March 2023.

[72] OpenAI, “OpenAI API”.

<https://platform.openai.com/> [Accessed 18 September 2023].

[73] S. Bubeck, “Sparks of artificial general intelligence: Early experiments with GPT-4”.

<https://arxiv.org/abs/2303.12712> [Accessed 20 November 2023].

[74] International Standards Organisation, “IEC 62304:2006 Medical device software - Software life cycle processes”, May 2006.

<https://www.iso.org/standard/38421.html> [Accessed 18 September 2023].

[75] BSI Group, “What regulators expect from medical device manufacturers of software with artificial intelligence (AI) & machine learning (ML)”, 04 March 2021.

<https://www.bsigroup.com/globalassets/meddev/localfiles/en-gb/documents/bsi-md-de-qa-medical-webinar-samd-uk-en.pdf> [Accessed 18 September 2023].

[76] Dot Compliance, “Resource blocks archive”.

<https://www.dotcompliance.com/resources/> [Accessed 18 September 2023].

Direct to download request form: <https://info.dotcompliance.com/why-ai-is-critical-in-medical-device-quality-management>

ENDS

Version Information

Version 2.7

Based on v2.6

Created 22 December 2024
Last saved: 22 December 2024

Version history:

Version 2.5 changes (c.f. v2.4)

Section 3.2: Software Bill of Materials (SBOM)
Section 3.7: Clinical information systems (CIS)
Section 6.1.1, 6.1.5, 6.1.6: EU AI Act related.
Section 6.13: AI ethics etc
Section 6.14. The UK's "AI Airlock"
Section 10: EUDAMED delays
Section 14: Delays in the standards harmonisation process

Version 2.6 changes (c.f. v2.5)

Section 6.7.4: Regulatory issues and controversies surrounding LLMs used in healthcare
Section 6.13: New references added

Version 2.7 changes (c.f. v2.6)

Section 12.1: New paragraph on the new (2024) EU Product Liability Directive.